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Chemoresistance is a major clinical problem in the treatment of cancer, and is thought 
to be related to an underlying resistance to apoptosis (programmed cell death) in cancer 
cells. In the present study, Burkitt’s lymphoma (BL)-derived B cell lines were used to 
investigate the intracellular signaling pathways involved in apoptosis induction by 
chemotherapeutic agents; in particular, we focused on post-mitochondrial signaling 
and its implications for chemoresistance. 
 
Apaf-1 (apoptotic protease-activating factor-1) is the main component of a protein 
complex termed the apoptosome, which is required for caspase activation downstream 
of mitochondria. Upon release from these organelles, cytochrome c binds to Apaf-1 
thus driving its oligomerization; this results in the activation of caspase-9 and caspase-
3, and the rapid dismantling of the cell. In the B cell lines utilized herein, cytochrome c 
failed to stimulate apoptosome formation and caspase activation, and this was shown to 
be due to insufficient levels of Apaf-1 in the cytosolic compartment. However, the 
level of Apaf-1 in total cellular extracts was normal. Enforced expression of Apaf-1 
increased its concentration in the cytosol, restored cytochrome c-dependent caspase 
activation, and rendered the prototypic BL cell line Raji sensitive to etoposide- and 
staurosporine-induced apoptosis. Subsequent investigations revealed that, in Raji BL 
cells, the bulk of Apaf-1 was sequestered in the plasma membrane. Moreover, 
liberation of Apaf-1 using lipid raft-disrupting agents served to sensitize BL cells to 
chemotherapeutic drugs. Our studies also show that IAPs (inhibitor of apoptosis 
proteins) are highly expressed in BL cell lines. The combination of Smac peptides, 
which serve to antagonize IAPs, thereby alleviating caspase inhibition, and 
staurosporine triggered apoptosis in Apaf-1-overexpressing BL cells, but failed to do 
so in mock transfectants. Similar results were obtained when Smac peptides were 
added together with the proteasome inhibitor, lactacytsin. Hence, Smac-mediated 
potentiation of apoptosis was shown to be Apaf-1-dependent, and IAPs were 
concluded to modulate the sensitivity to apoptosis in this model.  
 
In sum, these studies are the first to show that plasma membrane sequestration of Apaf-
1, a key component of the apoptosome, may render cancer cells resistant to treatment. 
From the point of view of clinical utilization of apoptosis-targeted therapies, our results 
suggest that IAP modulation using, for instance, Smac peptides or Smac mimetics, may 
be beneficial only if sufficient amounts of Apaf-1 are present. Our results also suggest 
that proteasome inhibition-triggered apoptosis is dependent on apoptosome formation. 
The latter findings may be of potential importance since clinical trials using 
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1. B CELL LYMPHOMA 
 
Cancer is, essentially, a genetic disease (Vogelstein and Kinzler, 2004), and resistance 
to apoptosis is one of several cardinal features of most cancer cells (Hanahan and 
Weinberg, 2000). B cell lymphomas (the focus of the present thesis) are a diverse 
group of malignant disorders that vary with respect to their molecular features, 
genetics, clinical presentation, treatment approaches, and outcome. Over the past few 
years, through an increased understanding of the biology of these diseases, new 
therapies, including a combination of cancer-targeted antibodies and chemotherapy, 
or new chemotherapeutic regimens, have been developed. The challenge of clinical 
research is to optimize the use of these agents, select those patients most likely to 
respond, and develop multi-targeted strategies based on a sound scientific rational, 
with the potential to increase the cure rate of patients with lymphomas (Cheson, 2004). 
 
1.1 Genetic background of Burkitt lymphoma  
1.1.1 c-MYC  
Burkitt’s lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma (NHL) 
consisting of endemic, sporadic, and immunodeficiency-associated variants. Eighty 
percent of BL cases harbor t(8;14), resulting in the juxtaposition of the c-myc gene on 
chromosome 8 with IgH enhancer elements on chromosome 14 which drive c-Myc 
mRNA and protein production. In the remaining 20% of BL cases, translocations 
occurring between chromosomes 2 and 8, t(2;8)(p12;q24), or chromosomes 8 and 22, 
t(8;22)(q24;q11), place the c-myc gene adjacent to either κ or λ light chain loci and 
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enhancer elements , respectively. As heavy chain and light chain loci are specifically 
active in mature B cells, it is not difficult to understand how c-myc transcription is 
favored in BL harboring t(8;14), t(2;8), or t(8;22) (Blum et al., 2004). C-Myc over 
expression is one of the most featured genetic backgrounds which directly or 
indirectly target expression of many genes involved in cell cycle regulation, apoptosis, 
cell growth, cell adhesion, and differentiation (Blum et al., 2004). It is also hard to 
attribute any one single alteration to lymphogenesis and chemotherapy responses.  
 
1.1.2 EBV status 
Epstein-Barr virus (EBV), a γ-herpesvirus, was discovered 40 years ago from 
examining electron micrographs of B cells cultured from BL specimens. Far from 
showing a restricted distribution, EBV was found to be widespread in all human 
populations and to persist in the vast majority of individuals as a lifelong, 
asymptomatic infection of the B-lymphocyte pool. Despite this, the link between EBV 
and endemic BL proved consistent and became the first of an unexpectedly wide 
range of associations discovered between this virus and tumours (Liston et al., 1997).  
EBV establishes a life-long latent infection within B lymphocytes. Latency is 
associated with the expression of as many as ten viral proteins, including a family of 
six nuclear proteins (EBNAs), three integral latent membrane proteins (LMPs) and the 
recently identified polypeptide RK-BARF0 (Kelliher et al., 1998). Several of these, 
most notably the EBNA-3 protein, elicit a strong EBV-specific cytotoxic T-
lymphocyte immune response. Through differential expression of EBV proteins that 
are immunogenic, potentially oncogenic, and those necessary for sustaining infection, 
equilibrium is established between infected B cells and the host’s immune 
surveillance. As a consequence, a relatively stable pool of latently infected cells is 
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maintained by the host. Thus, EBV is particularly well adapted for persisting within B 
lymphocytes of an immune host. As a result of the balanced relationship that exists 
between EBV and its host, pathogenesis associated with EBV latency is generally a 
consequence of either an immune deficiency, leading to EBV-induced immunoblastic 
lymphoma, or a known or suspected secondary genetic or environmental event that 
promotes full oncogenic transformation of latently infected cells (Kieff, E. 1996).  In 
contrast to tumors such as Hodgkin’s lymphoma and nasopharyngeal carcinoma, 
LMP-1 is not expressed in EBV positive BL, in which the pattern of viral gene 
expression, referred to as type I latency, is restricted to the proteins EBNA-1 which is 
required for EBV DNA maintenance. Even so, unlike c-MYC, there is no direct 
evidence that EBNA-1 contributes to tumorigenicity in EBV-associated malignancies 
(Wilson et al., 1996). Interesting results of in vitro experiments correlate EBV 
associated tumorigenesis of EBV-negative BL cells with an increased resistance to 
apoptosis that is coincident with down-regulation of c-MYC protein and increased 
expression of anti-apoptotic protein Bcl-2 (Ruf et al., 1999). Therefore, the relation of 
EBV with tumorigenesis, especially the role of apoptosis modulating the EBV related 
tumorigenesis has been the focus of a number of recent studies. 
 
1.2 Sensitivity of BL to chemotherapy 
In general, BL patients are sensitive to high-intensive chemotherapy; however, current 
treatments are suboptimal for some categories of patients (eg. patients with relapsed 
disease), and therefore other strategies are emerging to overcome the resistance in 
poor prognosis and relapsed disease, based upon a better understanding of the 
molecular basis of these tumors.  
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It is well established that chemotherapeutic drugs kill cancer cells by inducing 
apoptosis; conversely, dysregulation of the apoptosis program in a cancer cell may 
account for the failure of clinical treatment of cancer, including B lymphomas (Arnt et 
al., 2002). Hence, resistance to apoptosis may play a crucial role not only in 
carcinogenesis, but also in resistance to treatment with conventional therapies. In the 
current study, the mechanism of BL chemoresistance was investigated by directly 
targeting and dissecting apoptotic signalling pathways. A panel of human BL-derived 
B cell lines were used as an in vitro model system to decipher the molecular defects in 
apoptotic signalling as a mean to understand chemoresistance. 
 
2. APOPTOTIC SIGNALING PATHWAY 
 
Most, if not all, chemotherapeutic drugs trigger apoptosis, a form of programmed cell 
death (PCD), first described and characterized in the early 1970s by Wyllie and Kerr 
(Kerr et al., 1972). Apoptosis is a genetically controlled form of death which is 
important during embryonic development, negative selection of self reactive 
lymphocytes, and plays a crucial role in homeostasis of adult organisms (Jacobson et 
al., 1997). The phenomenon is based upon discreet morphological and biochemical 
changes observed during commitment and execution of the death signal (see later), 
followed by engulfment by neighboring cells, thus preventing a harmful inflammatory 
response (Fadeel et al., 2004). Being genetically regulated makes apoptosis amenable 
to therapeutic intervention.  
 
2.1 Genetic control of apoptosis 
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The initial insight into the genetic basis of apoptosis, was gained from ingenious 
studies on the nematode, Caenorhabditis elegans (Horvitz, 1999). These studies 
revealed a conserved pathway, whereby the products of two genes, designated ced-3 
and ced-4 (ced, cell death abnormal), were shown to be necessary and sufficient to 
trigger the perfectly timed and orchestrated death of 131 cells during the development 
of the worm. The relevance of this pathway to higher animals was established by the 
discovery of mammalian orthologs of these genes and the demonstration that the 
mammalian ced-3-related genes encode proteases (designated caspases) were 
responsible for the morphological changes associated with that of apoptosis 
(Hengartner, 2000). 
 
2.2 Apoptotic signaling pathways in mammals 
Due to the conserved molecular basis and biochemical processing in different species 
- from C. elegans, Drosophila melanogaster, to mammalian cells, a wide body of 
work has unraveled the intricate networks involved in apoptotic signaling and 
provided novel targets for better management of tumors that harbor defects or 
deficiencies in the signaling circuitry. Two main apoptotic pathways have been 
characterized in recent years, an intrinsic (mitochondria-dependent) pathway and an 
extrinsic (mitochondria-independent) pathway (Danial and Korsmeyer, 2004). Even 
though the initiator caspases for the two main apoptotic pathways are recruited and 
activated on the DISC and Apoptosome respectively and independently, the cross-talk 
between the two initiator caspases is bridged by other intracellular molecules, like 
BH3 only Bcl-2 family member Bid. Activated caspase-8 not only initiates 
mitochondria independent apoptotic pathway, also by targeting and cleaving Bid to 
truncated Bid (tBid) to activate the mitochondria dependent apoptotic pathway. tBid 
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inserts into the mitochondria outer-membrane, perturbs mitochondrial transmembrane 
potential and therefore motivates the mitochondrial release of cytochrome c. The 
released cytochrome c helps to oligomerize Apaf-1 to form the seven-spoked big 
protein complex, the apoptosome. The main apoptotic pathways are hence connected 
by tBid.  
In both cases, intracellular proteases belonging to the caspase family are processed 
through direct (linear) or feedback amplification steps. In the case of the latter, 
upstream initiator caspases are activated in one of two large protein complexes, 
namely the DISC (Death inducing signaling complex) and the apoptosome; (other 
platforms for caspase activation, such as the inflammasome and the PIDDosome, may 
also exist) (Martinon et al., 2002) (Tinel and Tschopp, 2004), and the executioner 
caspases being processed downstream of the initiator caspases in a cascade manner 
(Figure 1). 
 
3. THE APOPTOTIC MACHINERY 
 
3.1 Extrinsic (death receptor-mediated) apoptosis signaling: DISC formation and 
regulation 
3.1.1 Death receptors oligomerization initiates DISC formation 
Certain members of the tumour necrosis factor receptor (TNF-R) superfamily are 
involved in transducing apoptosis signals, and these proteins are therefore referred as 
the “death receptors” (DRs), a subset of type I transmembrane receptors TNF-R. 
Members of this family contain one to five cysteine-rich repeats in their extracellular 
domain, and a so-called death domain (DD) in their cytoplasmic tail. Studies 



















Figure 1. Apoptotic signaling pathway, the key role of apoptotic complex 
formation. Apoptotic complex in both extrinsic and intrinsic apoptotic signaling 
pathways serve to initiate and amplify executioner casapases in these two 
pathways. DISC formation provides executioner caspase-8 or caspase-10 platform 
to activation followed with extrinsic signals transduced into cells by death 
receptors. Intrinsic signals target to mitochondria and release proapoptotic factor-
cytochrome c to promote apoptosome formation which reaults in caspase-9 
activation.   
 8
DD is essential for transduction of the apoptotic signal by bringing about the physical 
assembly of a complex of molecules into a signaling complex, termed the DISC.  
CD95 (also known as Apo-1 or Fas) is one such family member and plays a 
significant role in the development of a functional immune system and in 
organogenesis (Krammer, 2000). The interaction between CD95 and its ligand 
(CD95L) induces receptor oligomerization, most probably a trimerization, of CD95 is 
required for transduction of the apoptotic signal and DISC assembly. The DISC forms 
within seconds of receptors engagement brought about by the adaptor FADD (Fas-
associated death domain protein) which binds via its own DD to the DD of CD95. 
FADD also carries a so-called death-effector domain (DED), and, again by 
homologous interaction, recruits the DED-containing pro-caspase-8 (also known as 
FLICE) into the DISC.  
Several different types of DISCs have been reported in cells undergoing apoptosis. 
The main difference in their molecular structure is the involvement of different 
bridging molecules, such as FADD or TRADD, which are initially controlled by 
oligomerization of different DRs. For instance, oligomerized CD95 (Fas) or TRAIL-R 
bridges FADD, and TNF-R1 oligomerization recruits TRADD as an adaptor to further 
recruit another DISC complex II to the complex I  (Micheau, and Tschopp, 2003).  
Even though the composition of the DISC varies depending on the DRs, the protein-
protein interactions (DD: DD and DED: DED) follow a common final pathway for 
execution of the extrinsic death signal.  
 
3.1.2 Capasee-8/ 10 activation  
Homotypic DED: DED interactions promote the binding of caspase-8 to FADD. In 
this manner, the DISC acts as a molecular scaffold in which caspase-8 is activated 
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(Medema et al., 1997). It is believed that the FADD-enforced high local concentration 
or “induced proximity” (Salvesen and Dixit, 1999), of caspase-8 monomers leads to 
dimerization of this caspase, triggering pro-caspase-8 autocatalytic processing to 
active caspase-8. Once cleaved, the active caspase-8 detaches into cytoplasm where it 
can proteolytically chew up a variety of cellular proteins, including pro-caspase-3 (the 
executioner), resulting in caspase-3 activation and dismantling of the cell. Hence, 
DISC formation in extrinsic signalling pathway is crucial to recruit apoptotic 
executioner, caspases. Although lacking in mice, humans also possess a second DED-
containing caspase, called caspase-10 (Hu et al., 1997; Ng et al., 1999). This caspase 
has a high degree of homology to caspase-8, likely the result of a gene duplication 
event via its proximity to the caspase-8 locus on human chromosome 2q33-q34. 
Caspase-10 has also been shown to potently induce apoptosis in a manner similar to 
caspase-8 (Kischkel et al., 2001; Sprick et al., 2002; Wang et al., 2001), and naturally 
occurring mutations in this caspase have been shown to lead to autoimmune 
lymphoproliferative syndrome (ALPS) (Wang et al., 1999). However, recent evidence 
suggests that its substrate specificity may be distinct from caspase-8.  
cFLIP is an additional molecule that is recruited to the DISC in many cases. It is 
likely the result of a gene duplication event like caspase-10 in humans, although it is 
also present in mice. cFLIP has a high degree of sequence homology with caspase-8. 
A short form encodes a truncated protein containing only amino terminal tandem 
DEDs and a short region of unique sequence, whereas a long isoform encodes a 
molecule very similar to caspase-8 but lacking an active site cysteine necessary for 




3.2 Intrinsic (mitochondria-dependent) apoptosis signaling: apoptosome 
formation and activation 
For most chemotherapeutic drugs, the preferred pathway is the mitochondria-
dependent intrinsic signaling pathway. The identification of mitochondrial proteins as 
the critical amplification factors involved in boosting the death signal provided the 
basis for the intrinsic apoptotic pathway. Mitochondria are activated either directly or 
indirectly by chemotherapeutic drugs or other forms of cellular stress (Green and 
Kroemer, 2004). In the latter case, active forms of BH3-only Bcl-2 family members, 
such as truncated Bid, translocate from the cytoplasm to the mitochondrial outer 
membrane and trigger a dissipation of mitochondrial transmembrane potential and 
release of cytochrome c from mitochondria. The release of pro-apoptotic molecules 
from mitochondria serves to initiate the formation of the apoptosome.  
 
3.2.1 Cytochrome c and its role in induction of apoptosome formation 
The role of mitochondria in apoptosome formation was first studied by the discovery 
that the mitochondrial inner membrane protein cytochrome c is released by apoptotic 
stimuli (Zou et al., 1997). Cytochrome c is a small (in mammals, 104 amino acid 
residues) and stable hemoprotein containing covalently bound heme c as a prosthetic 
group.  
In 1996 Wang and co-workers (Liu et al., 1996) discovered that cytochrome c was 
involved in apoptosis. As a model of apoptosis, treatment of cell-free S100 cytosolic 
extract from HeLa cells with dATP was used. It was found that the addition of dATP 
to the extract resulted in typical apoptotic changes, i.e. (i) cleavage of the caspase-3 
precursor yielding active caspase-3, (ii) nuclear DNA fragmentation and (iii) specific 
morphological changes in the cell nucleus. Fractionation of the extract revealed the 
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existence of at least two factors necessary to the above effect. Cytochrome c proved to 
be one of them. In other experiments it was shown that treatment of HeLa cells with 
staurosporine, a potent pro-apoptotic agent, caused cytochrome c release from 
mitochondria to the cytosol. Similar findings were reported in human embryonic and 
monoblastic cell lines. In 1997, the above observations were confirmed and extended 
by Wang's (Yang et al., 1997) and Newmeyer's (Kluck et al., 1997a; Kluck et al., 
1997b) groups.  
 
3.2.2 The composition and activation of the apoptosome 
 
3.2.2.1 Apoptosome components 
Based on these early studies of cytosolic cytochrome c initiating apoptosis both in 
vivo and in vitro, Wang and colleagues (Li et al., 1997b; Zou et al., 1997) identified 
the cytosolic partner of cytochrome c in the apoptotic cascade. This proved to be a 
protein showing significant sequence homology to Ced-4, a Caenorhabditis elegans 
factor activating pro-caspase-3. The protein, called apoptotic protease activating 
factor 1 (Apaf-1), possesses a nucleotide binding site apparently responsible for 
binding of dATP, a cofactor of apoptosis. It was shown that addition of (i) Apaf-1, (ii) 
cytochrome c (previously Apaf-2) and (iii) dATP to pro-caspase-9 (previously Apaf-3) 
results in conversion of pro-caspase-9 to active caspase-9. The Apaf-1, cytochrome c, 
dATP and caspase-9 therefore, form the so-called apoptosome (Figure 2).    
 
3.2.2.2 Evidence of Apoptosome formation by Gel Filtration 
Cytosolic cytochrome c binds to the adaptor protein Apaf-1 in its inactive form. The 





Figure 2. Apaf-1 isoforms and schematic model for apoptosome formation. A, 
Five different isoforms (from the NCBI gene database) are represented based on 
conserved CARD, NB-ARC (CED-4 homologue) and 12 or 13 WD40 repeats. The 
presence or absence of the 11 amino acids N-terminal insert following CARD and 
the 43 amino acids C-terminal insert between the fifth and the sixth WD repeats 
are also shown. B, Seven-spoked apoptosome formation. Cytosolic auto-inhibitory 
Apaf-1 is activated by exposing the CARD domain through cytochrome c and 
dATP/ATP binding to WD40 repeats and NB-ARC domain, respectively. Seven 
activated Apaf-1 monomers are prone to freely conform to a big complex which 
could recruit and activate procaspase-9. 
338aa
1205aa2 Isoform d
1 Isoform c 1248aaCARD NB-ARC WD40 (7) WD40 (6)
CARD NB-ARC WD40 (6) WD40 (6)
1237aa4 Isoform a CARD NB-ARC WD40 (7) WD40 (6)
1194aa5 Isoform b CARD NB-ARC WD40 (6) WD40 (6)




recruitment domain), a central CED-4 homology motif that binds dATP/ATP, and 12 
or 13 WD40 repeats in the C-terminal region (Dierlamm et al., 1999; Hu et al., 1998; 
Li et al., 1997a; Zou et al., 1997) (Figure 2). A truncated form of Apaf-1, isoform e, in 
which the WD40 repeats were removed, was no longer able to bind cytochrome c and 
was constitutively active (Hu et al., 1999; Srinivasula et al., 1998). Hence, the WD40 
repeats may function as intramolecular inhibitors of apoptosome assembly. This auto-
inhibition is overridden by cytochrome c, which promotes assembly of the 
apoptosome in the presence of dATP/ATP. Previous attempts to ascertain the 
composition and size of the apoptosome have relied largely upon gel filtration 
analysis (Cain et al., 2000; Cain et al., 1999; Rodriguez and Lazebnik, 1999). 
Thelatter studies indicate that the apoptosome, assembled either in vitro, or detected 
in dying cells, was found in two forms: ~700-kDa apoptosome that was 
proteolytically active (i.e., are capable of activating caspases-3 and -7) or an 
apparently inactive ~1.4-MDa apoptosome (Cain et al., 2000; Cain et al., 1999; 
Rodriguez and Lazebnik, 1999).It is currently unclear why the 1.4-MDa form of the 
apoptosome is functionally inactive. 
 
3.2.2.3 Visualization of Apoptosome Formation by Electro-Microscopy 
Recent, elegant structural studies have revealed the process of apoptosome assembly 
(Acehan et al., 2002). As mentioned in the preceding paragraph, in healthy cells, 
Apaf-1 normally adopts an auto-inhibited conformation in which the CED-4 domain 
may interact directly with the β propellers of the WD40 domain. Upon apoptotic 
signaling, cytosolic cytochrome c displaces the CED-4 domain by interacting with the 
WD40 domain, thus enabling Apaf-1 to bind dATP/ATP. Upon nucleotide binding, a 
second conformational change promotes assembly of the apoptosome. The rather 
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stably exposed CARD domain thus oligomerizes into a seven-spoked complex (i.e. a 
seven-spoked “wheel of death”), which allows caspase-9 binding and processing 
(Figure 2). The crystal structure of Apaf-1 provided the structural basis for the 
interaction with caspase-9. In the normal cells, Apaf-1 binds with ADP which is 
essential for maintaining the Apaf-1 auto-inhibitory conformation (Riedl et al., 2005).  
The 2.2-A° crystal structure of an ADP-bound, WD40-deleted Apaf-1, revealed the 
molecular mechanism by which Apaf-1 exists in an inactive state before ATP binding. 
The amino-terminal CARD packs against a three-layered α/β fold, a short helical 
motif and a winged-helix domain, which results in the burial of the caspase-9-binding 
interface. The deeply buried ADP molecule serves as an organizing centre to 
strengthen interactions between these four adjoining domains, thus locking Apaf-1 in 
an inactive conformation (Figure 3). Apaf-1 binds to and hydrolyses ATP/dATP and 
their analogues. The binding and hydrolysis of nucleotides seem to drive 
conformational changes that are essential for the formation of the apoptosome and the 
activation of caspase-9 (Figure 3). 
 
3.2.2.4 Processing and activation of caspases by apoptosome formation 
As for caspase-8, self-priming by means of dimerization is required for the activation 
of full-length caspase-9 (Boatright et al., 2003; Renatus et al., 2001). Caspase 
activation is induced by dimerization, with interactions at the dimer interface 
promoting reorientation of the activation loop. These observations support a model in 
which recruitment of caspases by the apoptosome creates high local concentrations of 
caspase-9 to provide a pathway for dimer-induced activation. Pro-caspase-9 firstly 
binds to the central hub of the apoptosome through a CARD-CARD interaction. The 
high local concentration of pro-caspase-9 on the hub may then facilitate the 
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Figure 3. Overall structure of the WD40-deleted Apaf-1 bound to ADP. A 
ribbon diagram of the structure of Apaf-1 (residues 1–591) bound to ADP. Apaf-1 
sequentially comprises five distinct domains: CARD (coloured green), an a/b fold 
(blue), helical domain I (cyan), a winged-helix domain (magenta) and helical 
domain II (red). These five domains pack against one another to generate a 
relatively compact structure. ADP binds to the hinge region between the a/b fold 
and helical domain I but is also coordinated by two critical residues from the 
winged-helix domain. (Reidl SJ., et al., 2005). 
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recruitment of monomers from solution to form dimers. Importantly, each of the pro-
caspase-9 dimers would contain a single active catalytic site. Proteolysis of the 
interdomain loop would then generate mature caspase-9, which can then process and 
activate pro-caspase-3. Again, similar to the mature active form of caspase-8, caspase-
9 could be autoprocessed to P35 and P12 fragments and be further cleaved to P37 and 
P10 fragments by activated caspase-3. This feedback cleavage of caspase-9 by 
caspase-3 significantly increases the activity of the apoptosome (Acehan et al., 2002; 
Boatright et al., 2003; Zou et al., 2003). Moreover, studies suggest that pro-caspase-3 
could be recruited to the apoptosome and be further processed by active caspase-9 
(Cain et al., 2000; Hill et al., 2004). The end result of apoptosome-driven caspase-3 
activation is the proteolytic cleavage of various cellular substrates and death of the 
cell. 
 
4. CHEMORESISTANCE: DEFECTIVE APOPTOSOME ACTIVATION IN 
APOPTOTIC SIGNALING PATHWAY 
 
Chemoresistance may result from defects in apoptosis signaling in cancer cells. In 
principle, this may result from a lack of pro-apoptotic proteins (eg. as a result of 
hypermethylation and silencing of caspases), or from over-expression of apoptosis 
inhibitors, or both. There are numerous examples of anti-apoptotic proteins that are 
over-expressed in variety of tumors, including anti-apoptotic Bcl-2 family members 
(Bcl-2, Bcl-XL, Mcl-1, and others), as well as survivin and other inhibitor of 
apoptosis proteins (IAPs), heat shock proteins (HSPs), and so forth (Arnt et al., 2002; 
Soengas and Lowe, 2003). Since most chemotherapeutic drugs induce apoptosis in 
mitochondria-dependent manner, this study was designed to understand the role of 
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pre/post-mitochondrial events, specifically the role of the apoptosome assembly and 
the IAPs in the resistance of BL cells to chemotherapy. 
 
4.1 Regulation of Apoptosis by anti-apoptotic members of Bcl-2 family 
4.1.1 Bcl-2 family members 
As introduced above, the intrinsic pathway of apoptosis is activated in response to 
many stimuli, including radiation and chemotherapeutic drugs, and the mitochondria 
play a central role in the mediation of this apoptotic pathway by providing a number 
of pro-apoptotic molecules, normally sequestered within its intermembrane space. In 
response to signals activating this pathway, the mitochondrial outer membrane 
permeabilization (MOMP) is triggered, and pro-apoptotic molecules are released into 
the cytosol initiating the caspase proteolytic cascade, as well as caspase independent 
cell death pathways. Whilst the precise mechanism of action is far from clear, Bcl-2 
inhibits this pathway by maintaining mitochondrial membrane integrity.  
Bcl-2 (B-cell lymphoma 2) is translocated to an immunoglobulin locus (t14;18) in 
follicular lymphoma, and inhibits cell death (Moriishi et al., 1999). This finding gave 
birth to the concept, now widely embraced, that impaired apoptosis is a crucial step in 
tumorigenesis. In mammals, Bcl-2 has at least 20 relatives, all of which share at least 
one conserved Bcl-2 homology (BH) domain. The family includes anti-apoptotic 
proteins (Bcl-2, Bcl-XL, and Mcl-1), and two groups of pro-apoptotic proteins (Bax, 
and its homologues, and BH3-only proteins, such as Bid, Bim, PUMA and Noxa). 
BH3 domain mediates protein-protein interactions and is necessary for the promotion 
of apoptosis. These BH3-only proteins respond to a number of signals to initiate the 
intrinsic apoptotic pathways and can interact with Bcl-2 like proteins inhibiting their 
function. For example death receptor activation mediates the activation of caspase-8, 
 18
this protease cleaves the BH3-only protein Bid to generate a truncated form (tBid). 
tBid translocates to mitochondria triggering MOMP, coupling death receptor 
signaling to the activation of the intrinsic pathway of apoptosis.  In contrast, the BH3-
only proteins PUMA and Noxa are transcriptionally activated by p53 and related 
family members, and are critical mediators of p53 and chemotherapy induced 
apoptosis (Nakano K, Mol Cell, 2001; Oda E, Science, 2000; Yu J, Zhang L, Mol Cell, 
2001; Jeffers, JR, Cancer Cell, 2003). 
 
4.1.2 Anti-apoptotic function in intrinsic apoptotic pathway- inhibition of 
cytochrome c release and apoptosome formation  
Bcl-2 inhibits apoptosis in response to many, but not all, cytotoxic insults, and the 
regulation of cell death may be cell type-specific (Scaffidi et al., 1998; Strasser et al., 
1995). The hydrophobic C-terminal domain of these proteins helps target them to the 
cytoplasmic face of intracellular membranes, including mitochondrial membranes, the 
endoplasmic reticulum (ER), and the nuclear envelope. Bcl-2 is an integral membrane 
protein, even in viable cells, whereas Bcl-XL only becomes tightly associated with the 
membrane after a cytotoxic signal. The anti-apoptotic function of Bcl-2 is mainly 
targeted to the control of other pro-apoptotic Bcl-2 relatives. Hence, Bcl-2 and Bcl-
XL presumably function at the mitochondrion to prevent Bax/Bak oligomerization 
which is believed to yield channels for the release of cytochrome c or other 
intermembrane proteins from these organelles (Gross et al., 1999). 
The role of Bcl-2 in inhibition of cytochrome c release has been widely studied.  It 
appeared that staurosporine-induced release of cytochrome c to cytosol of human 
acute myeloid leukemia cells was blocked by overexpression of the anti-apoptotic 
Bcl-2 protein, present in the outer mitochondrial membrane (Yang et al., 1997).  
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Similarly, the release of cytochrome c from mitochondria upon treatment with diverse 
apoptogens (ultraviolet treatment, etoposide, staurosporine, actinomycin D or H2O2) 
and its retention in Bcl-2-overproducing cells was reported. Likewise, addition of the 
Baculoviral-expressed Bcl-2 to Xenopus egg mitochondria slowed down the release 
of cytochrome c from these mitochondria incubated in the presence of cytosol. 
Furthermore caspase-3 activation by the combined action of cytosolic fraction and 
purified cytochrome c was confirmed (Kluck et al., 1997a). 
 
4.1.3 Bcl-2 family members in chemoresistance of B cell lymphoma 
Both in vivo and in vitro data have demonstrated a role for Bcl-2 family members in 
chemoresistance. For instance, biopsy samples from aggressive NHL were used to 
screen for Bcl-2, Bcl-X, Bax, and Bak expression (Bairey et al., 1999). These studies 
showed that the expression of Bcl-2, Bcl-X, and Bax alone or in combination is 
associated with chemoresistance and short term survival. Although Bcl-2 was first 
cloned as the t(14;18) translocation breakpoint from human follicular B-cell 
lymphoma, it has become apparent that many cell types express high levels of Bcl-2 
and/or Bcl-xL as a result of transcriptional up-regulation. In fact, several transcription 
factors have been demonstrated to activate the expression of Bcl-2, including NF-қB 
(Kurland et al., 2001). Bcl-X was also shown to be regulated by NF-қB in CD40-
mediated B cells survival (Lee et al., 1999).  
 
4.1.4 Bcl-2 as the potential target for cancer treatment 
Given the critical role of Bcl-2 and functionally related proteins in drug resistance, 
successful antagonists of Bcl-2 family members may have broad applicability in 
cancer treatments. In addition to mutations that increase Bcl-2 or Bcl-XL in tumors, 
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radiation and chemotherapy trigger apoptosis by mitochondria dependent pathway, 
therefore inhibition of their function may increase the response to standard therapies. 
Antisense oligonucleotides targeting Bcl-2 mRNA, and BH3-mimicking small-
molecule drugs have been tested in vitro for potential clinical application (Reed, 
2003). Antisense technology utilizes short synthetic stretches of DNA that are 
complementary to specific regions of the target mRNA. DNA binding to mRNA 
results in the inhibition of gene expression, by blocking translation of the mRNA or 
targeting the mRNA for RNAseH cleavage. Genasense is a phophorothioate oligo 
nucleotide complementary to the first 6 codons of Bcl-2. This modification renders 
the oligo more stable in vitro, and can efficiently down regulate Bcl-2 expression. In 
xenograft experiments, Genasense was able to inhibit tumour formation, and the 
effect was enhanced by combination with chemotherapeutic drugs (Cotter FE, 
Haematologica, 1999). This treatment is currently in phase III clinical trials for a 
number of malignancies including chronic lymphoblast leukaemia, multiple myeloma 
and melanoma after positive clinical responses in phase I/II trial for chronic 
lymphoblast leukaemia (Marcucci et al., 2003). 
 
4.2 Defective expression of Apaf-1 and chemoresistance 
Apaf-1 is ubiquitous in human tissues; however, the highest expression levels are seen 
in adult spleen, peripheral blood leukocytes, and in fetal brain, kidney and lung. There 
are five isoforms, classified and sequenced from normal human tissues, and in cancer 
cells (Figure 2). These isoforms are derived from different splicing. Even though they 
show different capacities in activating caspases in vitro (Benedict et al., 2000), there 
is no direct evidence that resistance to apoptosis could be explained by the expression 
of specific variants of Apaf-1, although one report has shown that cytosolic extracts 
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from K562 cells expressing an alternative Apaf-1 (Apaf-1XL) were more resistant to 
cytochrome c-dependent activation of caspase-3 (Fu et al., 2001). However, defective 
Apaf-1 expression, rather than expression of different isoforms of the protein, could 
contribute to resistance to apoptosis. Indeed, loss of Apaf-1 due to hypermethylation 
of the promoter region was reported in chemoresistant melanomas, and demethylating 
agents were shown to restore Apaf-1 expression and rescue the defective apoptosis in 
these cells (Soengas et al., 2001). Similarly, resistance of certain leukemia cell lines to 
UV irradiation-induced apoptosis was shown to be associated with defective 
expression of Apaf-1 (Fu et al., 2003; Jia et al., 2001). Impaired apoptosome 
activation has also been documented in ovarian carcinoma cell lines, but could not be 
explained by Apaf-1 deletion, degradation, or mutation (Liu et al., 2002; Wolf et al., 
2001). Furthermore, a loss of Apaf-1 expression has been demonstrated in human 
skeletal muscle cytosols, which are refractory to cytochrome c-dependent caspase 
activation (Burgess et al., 1999). In conclusion, apoptosome formation is a key event 
in intrinsic apoptosis signaling, and defective expression and/or activity of Apaf-1, the 
principal component of the apoptosome, may account for resistance to apoptosis in 
cancer cells. 
 
4.3 Heat Shock Proteins as inhibitors of apoptosome formation  
Heat shock proteins (HSPs) are a family of highly conserved proteins that are induced 
in response to a variety of cellular stresses, and function to protect the cell. These 
proteins have been found to inhibit apoptosome formation in a number of reports, thus 
serving to suppress apoptosis in response to physiological and environmental stresses 
(Beere and Green, 2001).  
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Hsp70 is a central protein in the cellular stress response system. Hsp70 has been 
shown to bind to the CARD domain of Apaf-1, with the resultant inhibition of 
apoptosome formation including an inability to recruit procaspase-9 to the complex 
(Beere et al., 2000; Saleh et al., 2000). Different reports have disputed whether Apaf-
1 oligomerization is able to proceed in the presence of Hsp70 (Beere et al., 2000; 
Saleh et al., 2000). Interestingly, studies suggest that Hsp70 also functions to inhibit 
apoptosis independently of its effect on apoptosome formation. In Apaf-1-/- mouse 
embryo fibroblasts, Hsp70 overexpression protects the cells from apoptosis following 
serum withdrawal (Ravagnan et al., 2001). Hsp70 carries out this function by binding 
to apoptosis-inducing factor (AIF), a mitochondrial intermembrane flavoprotein that, 
upon release into the cytoplasm, translocates to the nucleus and induces caspase-
independent apoptosis (Susin et al., 1999). Both Hsp90 and Hsp27 have also been 
shown to inhibit apoptosome formation. Hsp90 binds to Apaf-1 and inhibits Apaf-1 
oligomerization and apoptosome formation in response to cellular stresses (Pandey et 
al., 2000). Studies suggest that Hsp27 inhibits apoptosome formation by binding to 
and sequestering both cytochrome c and caspase-3 (Bruey et al., 2000; Concannon et 
al., 2001). 
 
4.4 Other factors regulating apoptosome formation 
The modulation of apoptosome formation is a balance between pro-apoptotic and 
anti-apoptotic signals. It has been shown in in vitro experiments that apoptosis is 
regulated by intracellular potassium ion (K+) levels, with physiological intracellular 
K+ concentrations functioning to inhibit apoptosome formation by preventing Apaf-1 
oligomerization (Cain et al., 2001). This inhibition is overcome by increasing 
cytoplasmic concentrations of cytochrome c, and it is proposed that the mechanism 
 23
for K+ inhibition is through competition for cytochrome c binding sites on Apaf-1 
(Cain et al., 2001). This inhibition of apoptosome formation by physiologic 
concentrations of K+ may serve as a safety mechanism against initiation of the 
apoptotic cascade following the leakage of small amounts of cytochrome c from the 
mitochondria. Finally, recent work has demonstrated that the oncoprotein 
prothymosin-〈 (ProT) inhibits apoptosome formation (Jiang et al., 2003), which 
suggests that one mechanism by which the protein becomes oncogenic is through the 
inhibition of apoptosis. Pro-T has been described as a transforming oncoprotein in 
vitro, and is associated with some human cancers (Magdalena et al., 2000; Orre et al., 
2001). The precise molecular interactions by which ProT negatively regulates 
apoptosome formation have yet to be determined. 
 
4.5 Inhibition of apoptosome function by targeting caspases, the role of IAPs in 
chemoresistance 
There are currently eight human IAP family members: NAIP (also known as BIRC1), 
cIAP1 (also known as MIHB, hIAP1 or BIRC2), cIAP2 (also known as MIHC, hIAP1 
or BIRC3), XIAP (also known as hILP or BIRC4), survivin (also known as EPR-1 or 
BIRC5), Apollon (also known as BRUCE or BIRC6), Livin (also known as ML-IAP 
or BIRC7) and ILP-2 (also known as BIRC8) (Chauhan et al., 2003; Salvesen and 
Duckett, 2002; Stennicke et al., 1998) ( Figure 4A).  
 
4.5.1 Inhibition of caspases activation by IAPs 
These proteins share a common structural domain termed the BIR (Baculoviral IAP 
repeat) domain, through which some IAPs directly bind to and inhibit selected 
caspases. XIAP, cIAP1 and cIAP2 can bind to caspase-9 through their BIR3 domain, 
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and thereby inhibit the proteolytic processing of caspase-3 and caspase-9. XIAP also 
can bind active caspase-3 (Stennicke et al., 1998; Sun et al., 1999). Smac (second 
mitochondrial activator of caspases, also known as Diablo (Du et al., 2000; Verhagen 
et al., 2000); the first mitochondrial activator of caspases is, of course, cytochrome c) 
interacts with IAPs. Upon apoptotic stimulation, Smac is released from mitochondria 
to the cytoplasm, where it binds to IAPs and disrupts their ability to bind caspases. 
Some IAP family members also function as E2/E3 ubiquitin ligases that can help 
transport target proteins, such as Smac and caspases, to the proteasome for 
degradation (MacFarlane et al., 2002; Suzuki et al., 2001). Indeed, cIAP1 and cIAP2 
are E3 ubiquitin ligases for Smac and promote its degradation (Hu and Yang, 2003). 
Apollon was also found to facilitate proteasomal degradation of Smac (Bartke et al., 
2004; Hao et al., 2004). Interestingly, Smac induced apoptosis in Apollon-deficient 
cells, but not in Apollon-expressing cells. The latter results suggest that Apollon has 
an essential function in preventing Smac-induced apoptosis, at least in certain cell 
types. Omi/HtrA2 is a second mitochondrial-sequestered protein containing IAP 
binding motif for proteasomal degradation of IAPs. It is also a serine protease that can 
trigger cell death in an IAP independent manner (Sekine et al., 2005; Suzuki et al., 
2001; Yang et al., 2003b)  (Figure 4B). 
 
4.5.2 IAPs in B cell lymphoma 
Previous studies have shown that IAPs are up-regulated in B lymphomas. However 
the role of IAPs in chemoresistance in these tumours was not consistently proven 
(Brieger et al., 2004; Jiang et al., 2003; Schattner, 2002). Interestingly, NF-қB 
inhibition-induced apoptosis in multiple myeloma (MM) and BL cells is accompanied 
by rapid down-regulation of NF-қB-dependent anti-apoptotic gene products, 
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BIR1 BIR2 BIR3 RING
Figure 4. IAPs family members and schematic model for functional domains.
A, eight mammalian IAPs are characterized by different composition of functional 
domains: BIR, RING and CARD, NBD domains.  B, schematic figure shows IAPs
anti-apoptotic function by two ways. IAPs could directly interact with their 
substrates through their BIR domains. Therefore IAPs inhibit the pro-apoptotic 
proteins function by competitive binding caspases with Smac or Omi/HtrA2. 
Furthermore, their C-terminal RING domain functions as E2/E3 ubiquitin ligase
which could ubiquitinize binding proteins and transfer to proteasome to degrade 





including several IAPs (Piva et al., 2005). Furthermore, upon drug-induced apoptosis 
in B lymphoma cells, XIAP and cIAP-1 were downregulated and/or cleaved in a dose-
dependent manner, and XIAP was found to translocate from the cytosol to the nucleus 
(Nowak et al., 2004). Along the same lines, recent studies have shown that cell-
permeable, N-terminal Smac peptides are able to sensitize various types of cancer 
cells to apoptosis triggered by death receptor ligation or chemotherapeutic agents 
(Arnt et al., 2002; Fulda et al., 2002; Jia et al., 2003). Indeed, a lack of cytochrome c-
dependent activation of caspases due to elevated levels of XIAP was recently 
demonstrated in Hodgkin lymphoma-derived B cell lines, and the introduction of  
synthetic Smac peptides re-sensitized these cells to apoptosis (Kashkar et al., 2003). 
Smac-based therapies may thus represent a novel strategy in the treatment of cancer, 
including B lymphoma. 
 
5. OTHER KEY PLAYERS IN CHEMORESISTANCE, FROM BL GENETIC 
BACKGROUND 
5.1 EBV related proteins 
Some EBV-encoded proteins can regulate the apoptosis machinery of host cells 
directly or indirectly. For instance, LMP1 (latent membrane protein 1) protects B cells 
from apoptosis via upregulation of Bcl-2 (Henderson et al., 1991). On the other hand, 
LMP1 can also potentiate apoptosis triggered by chemotherapeutic drugs such as 
etoposide and cisplatin, at least in cells of epithelial origin (Zhang et al., 2005). From 
a historical perspective, EBV-positive BL-derived cell lines such as Raji were the first 
human cell lines of hematopoietic origin, and are widely used today as a model to 
study cancer (Karpova et al., 2005). Except for EBV encoded proteins involved in 
apoptotic features after EBV infection, it seems the most striking changes were due to 
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the secondary modulation, such as most well studied c-MYC and P53 status, after 
EBV induced transformation. The EBV status in the BL cell lines used in the study is 
shown in Table 1. 
 
5.2 c-MYC and P53 
The role of Myc in apoptosis is paradoxical and debated in different models. 
Interestingly, reactivation of Myc leads not to re-emergence of the tumour, but 
apoptosis (Jain et al., 2002). Deregulated c-myc may influence numerous cellular 
processes, including cell cycle regulation, apoptosis, cell metabolism, cell adhesion, 
and differentiation, and has been suggested to be important for lymphomagenesis 
(Sanchez-Beato et al; 2003). Due to its oncogenic feature, especially in BL cells, Myc 
could actually activate many apoptosis associated proteins. In general, both anti- and 
pro- apoptotic functions of these proteins have been studied by different groups (see 
below), the most well known of which are p53, NF-κB and the Bcl-2 family members.  
The pro-apoptotic role of c-myc has been demonstrated in B lymphoma-derived cell 
lines, as well as in cell lines from many other forms of cancer (Askew et al., 1991; 
Fanidi et al., 1992). Importantly, when inhibition of apoptosis (through expression of 
Bcl-2) is combined with activation of c-myc, lymphoid cancers can develop very 
rapidly, as shown in pioneering in vivo studies in transgenic mice (Strasser et al., 
1990). Interestingly, Bcl-2 is one of the target protein regulated by NF-қB, and 
cooperates with c-myc, which is of importance both for carcinogenesis and for the 
evolution of drug resistance in cancer cells (Fanidi et al., 1992). The tumour 
suppressor p53, in turn, induces the expression of numerous pro-apoptotic proteins, 
including Apaf-1, Bax, and other Bcl-2 family members 
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Cell line EBV status
DG75 Neg. Bassat-Ben et al. , 1977
Mutu I Pos. Gregory et al. , 1990
Mutu III Pos. Gregory et al. , 1990
Rael Pos. Klein et al. , 1972
Ramos Neg. Klein et al. , 1975
Ehlin-Henriksson et al. , 1987
Raji Pos. Pulvertaft 1964
Neg. negative, Pos. positive
Table 1. EBV status in BL derived cell lines used in the study.
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(Miyashita et al., 1994; Moroni et al., 2001; Nakano and Vousden, 2001; Oda et al., 
2000; Selvakumaran et al., 1994; Soengas et al., 1999). Moreover, recent studies 
suggest that p53 may also act independently of its transcriptional activity, through a 
direct, pro-apoptotic effect on mitochondria (Chipuk and Green, 2005).  
Mutations in p53 are the most common aberration in human cancer (Vousden and Lu, 
2002). Indeed, p53 mutations are relatively frequent in BL tumors (Gaidano et al., 
1991), as well as in BL-derived B cell lines (Farrell et al., 1991; Wiman et al., 1991). 
However, while some clinical studies stratified by p53 status found a correlation 
between inactivated p53 and poor clinical outcome, others were inconclusive (Schmitt 
and Lowe, 1999). These studies often concluded that p53 played no role in therapy-
induced cell death, yet conceptual pitfalls may have contributed to these results. For 
example, markers for mutated p53, such as strong immunohistochemical staining 
intensity, could have substantial error rates and extra-genetic mutations in the p53 
pathway able to compromise p53 function would be misclassified as wild-type p53 in 
studies addressing p53 sequence status only. For instance, recent observations suggest 
that de-regulated BCL6 expression may functionally inactivate p53, even in the 
absence of p53 mutations (Phan and Dalla-Favera, 2004). In any case, the 
aforementioned studies do not fully address the array of apoptosis defects that may 
account for chemoresistance, since not all apoptotic programs are dependent on p53 
(Jacobs et al., 1996; Schmitt and Lowe, 2002).  The p53 mutation in the BL cells used 






Cell line P53 status
DG75 WT Wiman et al. , 1991
Mutu I Mutant Wiman et al. , 1991
Mutu III Mutant Wiman et al. , 1991
Rael Mutant Wiman et al. , 1991
Ramos Mutant Farrell et al. , 1991
Raji Mutant Farrell et al. , 1991
Table 2. P53 status in BL derived cell lines used in the study.
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AIM OF THE STUDY 
 
Chemoresistance is a major problem in the treatment of cancer patients. Dysregulation 
of the apoptosis machinery in cancer cells may account for the failure of conventional 
cancer therapies. Using a panel of human cell lines as our model system, we aimed to 
dissect the underlying molecular mechanism(s) of chemoresistance in B lymphoma. 
The specific aims of our study were to determine: 
 
• The importance of apoptosome assembly and activation in the response of B 
lymphoma cells to chemotherapeutic drug-induced apoptosis 
 
• The importance of other apoptosis-modulating molecules, including IAPs and 
Smac, in the response of B lymphoma cells to apoptosis induction  
 
• The expression of other, mitochondria-targeted inhibitors of apoptosis in B 











MATERIAL AND METHODS 
 
In the present study, apoptosis was evaluated at several levels, including intact human 
cell lines and cell-free systems (Figure 5). The methods used in this work are 
summarized below. 
 
1. Cell lines  
BL-derived cell lines, Raji, Ramos, DG75, Rael, Mutu I, and Mutu III were obtained 
from the Microbiology and Tumor Biology Center (MTC) at Karolinska Institutet. 
The Jurkat T leukemic cell line, obtained from the European Cell Culture Collection 
(Salisbury, UK), was used as positive control since it has been reported to be sensitive 
to various apoptotic agents including chemotherapeutic drugs and its apoptosis 
signaling pathways have been carefully investigated (Weis et al., 1995). All these cell 
lines were grown in RPMI medium containing 10% FCS, 100U/ml penicillin, 
100μg/ml streptomycin, and 1mM glutamine at 37°C in an incubator with 5% CO2.   
 
2. Apoptosis-inducing agents and induction of apoptosis 
 The following apoptosis-inducing drugs were used in the present study: the 
topoisomerase II inhibitor, etoposide (Bristol-Myers, Solna, Sweden), the protein 
kinase C inhibitor, staurosporine (Sigma, St. Louis, MO), and the proteasome 
inhibitor, lactacystin (Calbiochem, San Diego, CA). In the pilot experiments, other 
chemotherapeutic drugs were also used at different doses to trigger apoptosis in Raji 
cells: topoisomerase II inhibitor, daunorubicin (Sigma, St. Louis, MO), anti-mitotic 
agent, taxel (Sigma, St. Louis, MO), RNA/DNA anti-metabolite, 5-aza-2'-
deoxycytidine (Sigma, St. Louis MO). However, they all failed to induce apoptosis in  
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Cell based level (in vivo)
Apoptosis assay;
Generation of stable overexpression cell line;
Intracellular protein distribution by confocal-fluorescent 
microscope.
Profiling apoptosis inhibitors.
Cell free system (in vitro)
S100 cytosolic
Apoptosome formation assay;
In vitro caspase activation assay;







RT-PCR and sequencing of Apaf-1;
Create DNA antisense target to apoptosis inhibit protein- Hsp27 
and silence intracellular Hsp27 protein. 
Figure 5.  Methodology flow chart. 
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Raji cells. In addition, cell-permeable Smac N7 peptides (manufactured by 
Calbiochem, the generous gift of Dr. Chengyun Zheng, Karolinska Institute) were 
used to alleviate IAP inhibition of caspases in the second part of this project.  
In the first part, cells in logarithmic growth phase were treated with 10μM etoposide 
or 1μM staurosporine for 24hrs, 48hrs, and 72hrs, in the presence or absence of 
zVAD-fmk (25μM; Enzyme Systems Products, Dublin, CA) or methyl-β-cyclodextrin 
(MCD) (100μM, Sigma). In the second part of this study, cells were pretreated with 
20μM Smac N7 peptides and followed by 1μM staurosporine or 10μM lactacystin 
treatment for 16hrs.  
Drug concentrations used throughout were based on prior experiments to optimize 
doses in the model systems.  
 
3. Generation of stable Apaf-1 over-expressing cell lines 
Wild type Raji cells growing in RPMI with 10% FBS were transfected with Apaf-1 
pcDNA3.1(-) plasmid (kindly provided by Dr. Xiaodong Wang, USA) by 
electroporation using a BioRad Gene Pulser. The transfection parameters were 
10x106/800μl cells in PBS, 950 mA current, and 10s electroporation shock to cells. 
Cells were then removed and directly placed into in RPMI1640 with 10% FBS growth 
medium. After 3 passages with geneticin (G418, Life Technologies) selection, cells 
were seeded in 96-well culture plates at 1 cell/well density in the selection medium. 
Single cell colonies were picked for further growth until cell numbers were sufficient 
for detection of Apaf-1 protein by Western blot. Five Apaf-1 over-expressing clones 
(detection of Apaf-1 protein level by western blot) were exposed to etoposide and 
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staurosporine, and three out of five clones were sensitive to apoptosis, when 
compared to mock-transfected Raji cell line. 
 
4. Apoptosis assays 
Classical apoptotic cell death can be defined by certain morphological and 
biochemical features that distinguish it from other forms of cell death. One such 
feature, which is a hallmark of apoptosis, is nuclear condensation and DNA 
fragmentation. In dying cells, DNA is cleaved by an endonuclease that fragments the 
chromatin into nucleosomal units, which are multiples of about 180-bp oligomers and 
appear as a DNA ladder when run on agarose gel. By visualization and quantification 
the apoptotic population, DNA dyes including membrane permeable Hoechst 33342 
and membrane impermeable propidium iodide (PI) were used in this study.  
 
4.1 Morphological assessment of nuclear condensation and fragmentation by 
Hoechst 33342 
Cell pellets were collected after cells were exposed to various stimuli. Resuspended 
cells in 20-50 μl PBS were dropped onto slides. Cells were stained with 10 μg/μl cell 
membrane permeable Hoechst 33342 (Molecular Probes) and apoptotic features 
(fragmented/condensed nuclei) were determined under fluorescence microscopy. 
Apoptotic cells were counted from three independent experiments and statistical 
analysis was performed by the student’s t-test using a p-value less than 0.05 (Figure 
6A). 
 
4.2 Analysis of DNA fragmentation by PI incorporation 
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Cells were stained with PI: RNase A (10μg/ml PI, from Molecular Probes, Leiden, the 
Netherlands, and 250μg/ml RNase A, from Sigma) after permeabilization with 70% 
ethanol. Samples were analyzed on a FACScan using the CellQuest software (Becton 
Dickinson, USA), as described by Nicoletti et al (Nicoletti et al., 1991). Data are 
shown as the percentage of cells displaying hypodiploid DNA content (Figure 6B). 
 
4.3 MTT Reduction assay 
The assessment of the degree or rate of cellular proliferation and cell viability is 
critical to the assessment of the effects of drugs. Tetrazolium-type indicator dyes, 3-
(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT), has been the most 
widely utilized. After drug exposure, 50μl MTT from the freshly made stock solution 
(3-5 mg/ml in plain RPMI) was added to each well of 96 well plates and incubated for 
2-3 hrs at 370C in the dark. The plates were centrifuged at 3000rpm for 5 minutes. 
Following decanting of the supernatant, the crystals (formazan) were dissolved in 
200μl DMSO +10μl Sorenson’s glycine buffer. Inhibition of cell proliferation was 
determined by measuring the absorbance at 570nm wavelength using an automated 
ELISA reader.   
 
4.4 Determination of caspase activities 
Caspase-3, caspase-8 and caspase-9 activities were determined using the fluorogenic 
peptide substrates, 50μM DEVD-AMC, 100μM IETD-AMC and 100uM LEHD-
AMC (BioMol, Plymouth Meeting, PA), respectively, as described previously by 
Nicholson et al (Nicholson et al., 1995). Cell lysates and substrates were combined in 
a standard reaction buffer and real-time measurements of enzyme-catalyzed release of 
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AMC were obtained using a Fluoroscan II plate reader (Labsytems, Stockholm, 
Sweden) operating with Genesis software (Labsystems). Fluorescence values were 
converted to picomoles of AMC release using a standard curve generated with free 
AMC and the maximum rate of AMC release (pmol /min) was calculated (Figure 7). 
 
4.5 Detection of membrane Phosphatidylserine (PS) exposure  
An early event during apoptosis is the flipping out of the inner membrane 
phospholipid, PS, to the outside. This exposure of PS occurs without any compromise 
in the plasma membrane integrity. Exposed PS could be detected by Annexin V 
(physiological ligand) conjugated with fluorescent substrates. At the same time co-
staining with cell membrane impermeable fluorescent dye, PI, could exclude necrotic 
cells where the membrane integrity has been impaired resulting in entry of PI. After 
treatment, 1x106 cells were collected and stained with Annexin V-FITC: PI (BD 
Bioscience) and analyzed by FACS flow cytometry.  
 
4.6 Analysis of mitochondrial transmembrane potential 
Loss of mitochondrial membrane potential was evaluated by the capacity of cells to 
update the potential-sensitive cationic fluorescent probe, tetramethylrhodamine, ethyl 
ester (TMRE). In brief, 0.5x106 cells were incubated with 25nM TMRE in 37℃ 
incubator for 20min before harvest cells. Cells were then pelleted, wash once in PBS 
and resuspended in HEPES buffer containing 25nM TMRE, and analyzed by FACS 
flow cytometry. CCCP is a membrane permeable proton ionophore. By disrupting 
mitochondrial membrane-potential, CCCP is always used as positive control for 
detection dissipation of ∆ψ in the study.  
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Figure 6. Apoptosis analysis by Hoechst 33342 staining and PI incorporation.
Jurkat cells were treated with medium or 10μ M etoposide to trigger apoptosis. A, 
Hoechst 33342 staining was used to observe apoptotic nuclear morphological 
change by fluorescence microscopy. Arrows indicate cells with the apoptotic 
nuclear changes at different stages: chromatin condensation, accumulation against 
nuclear membrane, and DNA fragmentation. B, Cell cycle analysis was used to 
evaluate apoptosis by quantifying sG1 (subG1) population. Cells were stained 
with PI and analyzed by FACS flow cytometry after treated with 
chemotherapeutic drug, etoposide. Apoptotic population was shown as the 













Figure 7. Time-dependent AMC release curves. Caspase 3 like proteases 
activity assay was performed by Genesis software. Activity was shown by
picomoles of AMC release from caspase substrate DEVD-AMC linearized at 
constitutive time points. ▲ indicates S100 cytosol was treated with buffer as 
control;  indicates S100 cytosol was treated with dATP and cytochrome c to 


























4.7 Detection of apoptotic related proteins by western blot analysis 
Total cell lysates, mitochondrial and cytosolic fractions were obtained using standard 
procedures (see each related method). Protein concentration was determined using the 
Bradford reagent (BioRad Laboratories) and samples were subjected to different 
concentrations of SDS-PAGE depending on the molecular weight of target proteins, 
followed by transfer to nitrocellulose membranes. In brief, 7.5% gel used for 
detecting Apaf-1, 10% gel for XIAP, cIAP1, cIAP2, Hsp70, and LMP1, and 12.5% 
for detecting caspase-3, caspase-9, Bcl-2, Smac, and cytochrome c. Immunoblotting 
was performed with the respective primary antibodies (see below), and proteins were 
visualized by enhanced chemiluminescence (BioRad Laboratories). 
Chemiluminescence densitometric analysis of membranes was performed using a Fuji 
Film Intelligent Darkbox II densitometer and Image Gauge 4.0 software (Fuji Film, 
Dusseldorf, Germany). Equivalent protein loading was confirmed by re-probing of 
membranes with antibodies to GAPDH or β-actin, as indicated.  
Antibodies list for western blot: Apaf-1 (Chemicon, Temecula, CA), Caspase-3 (BD 
Biosciences, San Diego, CA), caspase-9 (BD Biosciences), cytochrome c (BD 
Biosciences), poly(ADP-ribose) polymerase (PARP) (Biomol), GAPDH (Trevigen, 
Gaithersburg, MD), β-actin (Sigma), Smac (BD Biosciences), Bcl-2, (Santa Cruz 
Biotechnology, Santa Cruz, CA), cIAP1 (Santa Cruz Biotechnology), cIAP2 (R&D 
System, Minneapolis, MN), XIAP (Nordic Biosite, Taby, Sweden), LMP1 (generous 
gift from Dr. Zhang Xiangning from MTC, Karolinska Institutet), Hsp27 (Santa Cruz 
Biotechnology), and Hsp70 (Santa Cruz Biotechnology). 
 
5. In vitro cell-free systems 
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S100 cytosol was first used to identify cytosolic cytochrome c and apoptosome 
formation in vitro. It’s an effective method to evaluate apoptosome formation and 
activation by adding dATP and cytochrome c. Caspases processing, especially 
caspase-9 and caspase-3, was used to visualize apoptosome activation on the western 
blots.   
 
5.1 Generation of S-100 cytosols and cell-free apoptosis assays 
 At least 50x106 cells were collected and incubated with ice cold S-100 buffer 
containing protease inhibitors cocktail (Roche). Cells were disrupted using a Dounce 
homogenizer and centrifuged at 10,000g for 10 min. Supernatants were further 
centrifuged at 100,000 g for 1 h and the resulting supernatant (S-100 cytosol) was 
either stored at -80°C or used immediately. For cell-free caspase activation, 60μg S-
100 cytosol was incubated with 1 mM dATP and 4 μM cytochrome c for 30 min at 
30°C, as described by Liu et al (Liu et al., 1996). Aliquots were then collected for 
assessment of pro-caspase processing by Western blot and caspase activity by 
fluorogenic assay. For granzyme B-induced caspase activation, 60μg S-100 cytosols 
were incubated with 2U human recombinant granzyme B from E.coli (≥7.0 units/μg 
protein. One unit is defined as the amount of enzyme that will hydrolyze 1 nmol of 
Ac-IEPD-pNA per minute at 25℃, pH 8.0. EC 3.4.21.79.) (Calbiochem Nottingham, 
UK). 
 
5.2 Assessment of apoptosome formation 
 S-100 cytosolic extracts were incubated in the presence or absence of dATP and 
cytochrome c to trigger apoptosome formation. S-100 cytosols were then loaded on a 
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SephacrylTM S-300 (Amersham Bioscience, Uppsala, Sweden) gel filtration column at 
a flow rate of 0.5 ml/min using a Biologic HR workstation (BioRad). The column was 
calibrated with a gel filtration protein standard kit ranging from 10 KDa to 2000 KDa 
(Sigma). A total of 70 fractions were collected using a Fraction Collector FRAC-100, 
and aliquots from each fraction were protein precipitated with pure methanol. The 
protein pellet was dissolved with Laemmli’s buffer and resolved on SDS-PAGE gels, 




 Purified rabbit anti-cIAP1, anti-cIAP2 and mouse monoclonal anti-XIAP antibodies 
(for manufacture see Western Blot) were used for immunoprecipitation. Protein A/G 
sepharose 4FL (Amersham Bioscience, Uppsala, Sweden) beads were precleared with 
S-100 buffer and incubated overnight with S-100 cytosol and the specific primary 
antibodies, as indicated. Immunoprecipitates were collected by centrifugation and 
denatured in Laemmli’s buffer prior to Western blot. Supernatants (i.e. 
immunodepleted cytosolic extracts) were incubated with cytochrome c and dATP and 
assessed for caspase-3 like protease activity.  
 
5.4 Cytochrome c and Smac release 
 Cytochrome c and Smac release were evaluated by Western blot through a 
comparison of the expression in cytosolic versus mitochondrial fractions. To obtain 
these fractions, cells were resuspended and incubated in buffer A for 20-30 min 
supplemented with 200ug/ml digitonin (Sigma) and protease inhibitors (Roche). Cell 
disruption was performed by passing cells through a 20-gauge needle 8-10 times (or 
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by centrifugation at 12,000 g directly after incubation with digitonin to get cytosolic 
enriched supernatants according to different cell lines). Homogenates were then 
centrifuged at 600g. Supernatants were collected and centrifuged at 12,000g, and 
supernatant (cytosolic fraction) and pellet (enriched for mitochondria) were recovered. 
The whole process was performed on ice. Samples were then denatured in Laemmli’s 
buffer and resolved on SDS-PAGE gels, followed by Western blot using anti-
cytochrome c and anti-Smac antibodies. 
 
6. Molecular approaches 
 
6.1 Apaf-1 sequencing 
RNA was isolated from Raji cells by RNeasy Mini Kit (QIAGEN). First strand DNA 
was synthesized using RT kit from Life Technologies. The primer was targeted to 
Apaf-1 mRNA downstream of stop codon, 5’ tactgcacaacaattaagagct 3’. Elongase 
from Invitrogen was used to amplify DNA. We designed 5 pairs of primers target 
3747 bps Apaf-1 mRNA isoforms c, 1: 5’ tggttgacagctcagagag 3’, 5’ 
attactgaatctgtaacactc 3’, 2: 5’ gcttttgacagtcagtgtca 3’, 5’ atcagatgagcagggccta 3’, 3: 5’ 
ccctggattggattaaagca 3’, 5’ cccaaagctttaaggttcca 3’, 4: 5’ ttggctagttgttcagctga 3’, 5’ 
gtcttctcatcggctgtga 3’, 5: 5’ ctgtatggcacatccagtt 3’, 5’ agttgatatcagggtttcatta 3’. Using 
these 5 pairs of primers a total of 6 fragments of PCR products were amplified. PCR 
products were purified from agrose gel using QIAquick Gel Extraction Kit from 
QIAGEN. Sequencing reactions were then performed using a BigDye Terminator 
v3.1 Cycle Sequencing Kit from Applied Biosystems. All the primers used were 
obtained from Invitrogen.  
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6.2 AsHsp27 (antisense) pCDNA3.1 (+) construct 
 Heat shock protein (Hsp)27 cDNA was obtained from DG75 and Ramos cells using 
the following primers with insertion of BamH I and EcoR I cutting sites: sense 5’ 
gaggaattcagcagagtcagccagcatg 3’, and antisense 5’ gagggatccccgggctaaggctttacttg 3’, 
and were digested with BamH I and EcoR I enzymes. Reverse cloning of Hsp27 
cDNAs into the pCDNA3.1 (+) vector was performed using BamH I and EcoR I. 
Transformed Hsp27 antisense pCDNA3.1 into Escherichia coli XL-1 blue strain and 
positive colonies were screened by PCR reaction to see antisense target and by 
digestion with BamH I and EcoR I for target fragment on agarose gel. Purified 
positive colony was sequenced following BigDye Terminator v3.1 Cycle sequencing 
reaction. BL cell lines were then transiently transfected with the antisense construct 
using the DMRIE-C transfection reagent from Invitrogen.  
 
6.3 Transient transfection of AsHsp27 
12 well plates were used for transient transfection. Antisense DNA (1 and 2μg) was 
mixed with 250μl OPTI-MEM (Invitrogen) before adding into 12 well plates 
containing transfection reagent DMRIE-C (Invitrogen) in 250μl OPTI-MEM in each 
well. The mixture was incubated at room temperature for 30 min. 1x106 cells diluted 
in 100μl OPTI-MEM were dropped on DNA-DMRIE-C mixture in each well and 
then incubated overnight, and 1ml fresh normal culture medium (RPMI1640 with 
10% FCS) was topped up. After 48hrs or 72hrs, cells were collected and lysates were 





Appendix: Buffers used in the study 
 
Annexin V binding buffer: 
10X Binding Buffer: 0.1 M HEPES, pH 7.4, 1.4M NaCl, 25mM CaCl2 . dilute to 1X 
by dH2O prior to use.  
 
HEPES Buffer for TMRE staining:  
HEPES buffer: 10mM HEPES, 150mM NaCl, 5mM KCl, 1mM MgCl2 and 1.8mM 
CaCl2, pH 7.4 
 
Substrate Buffer for DEVD-AMC: 
100mM HEPES, 10% sucrose, 0.1% CHAPS, pH 7.25, before running 5mM DTT and 
10-6% NP-40 added into buffer 
 
Substrate Buffer for LEHD-AMC: 
100mM MES, 10% PEG, 0.1% CHAPS, pH6.5, before running 5mM DTT and 10-
6% NP-40 added into buffer 
 
Buffer for making SDS-Page gel: 
Separating gel preparation (0.375M Tris, pH8.8) 
 
Percentage of gel 15% 12% 10% 7.5% 5% 
dH2O (ml) 2.35 3.35 4.02 4.85 5.68 
1.5M Tris pH 8.8 (ml) 2.5 2.5 2.5 2.5 2.5 
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10%SDS 100μl 100μl 100μl 100μl 100μl 
30% Acrylamide/Bis (ml) 5 4 3.33 2.5 1.67 
10% APS 50μl 50μl 50μl 50μl 50μl 
TEMED 5μl 5μl 5μl 5μl 5μl 
Total volume 10 10 10 10 10 
Linear separating range (KD) 12-43  16-68 36-94 57-212 
 




  dH2O (ml) 7.29 
  1.0M Tris pH 6.8 (ml) 1.25 
  10%SDS 100μl 
  30% Acrylamide/Bis (ml) 1.3 
  10% APS 50μl 
  TEMED 5μl 
  Total volume 10ml 
 
Running buffer for SDS-Page gel: 10X (2L) 
Tris-base 60g, glysine 288g, SDS 20g, top to 2L with dH2O. 
 
Transfer buffer for western blot: 1X (5L) 
Tris-base 12.1g, glycine 57.84g, methanol 1L, top to 5L with dH2O. 
 
Lammeli loading buffer: 5X (10ml) 
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Tris-Hcl pH 6.8  3.1ml (1M), SDS 1g (10%), glycerol 2ml (20%), beta-Me 2.5ml 
(25%), BPB 0.01g (0.1%), top to 10ml with 2.4ml dH2O. 
 
Membrane stripping buffer: 1X (100ml) 
1M Tris-Hcl 6.25ml pH 6.8, B-Me 714ul, 10%SDS 20ml, top to 100ml with 66.8ml 
dH2O. 
 
Ponceau S Buffer: 
Ponceau S 0.1%, methanol 40%, acetic acid 15%. 
 
Cell lysates Buffer: 




20mM HEPES-KOH, pH7.5, 10mM KCl, 1.5mM MgCl2, 1mM Na-EDTA, 1mM 
EGTA, before using adding 1mM DTT, protease inhibitor and calpain inhibitors. 
 
Buffer A for detection cytochrome c and Smac release: 
50mM PIPES-KOH pH7.4, 220mM mannitol, 68mM sucrose, 50mM KCl, 5mM 
EGTA, 2mM MgCl2, before using adding 1mM DTT and protease inhibitor. 
 
Fluorescence Mounting Medium: 





1. Human BL-derived cell lines are resistant to apoptosis triggered by the 
chemotherapeutic drug, etoposide: evidence for a post-mitochondrial defect 
 
1.1. Raji B cells are resistant to etoposide-induced apoptosis 
Raji BL cell line and Jurkat T leukemic cell line were used to optimize the 
concentration of etoposide used throughout the study. As seen in Figure 8, Raji and 
Jurkat cells were treated with 2.5μM to 10μM etoposide, and cell viability was 
determined by MTT assay. Jurkat cells were relatively more sensitive to etoposide 
treatment, even at a low concentration of 2.5μM; there was nearly 20% cell death 
after 24hrs treatment. Increasing the concentration to 10μM resulted in a significant 
decrease in cell survival (30%), which could be partially inhibited by the general 
caspase inhibitor, zVAD.  However, there was no comparable decrease in cell 
viability of Raji cells incubated with 10μM etoposide. As MTT assay is an index of 
cell viability rather than actual cell death, to evaluate if decreased viability was due to 
cell death, Annexin V+ PI staining was performed to look at phophatidyl serine (PS) 
exposure. PS exposure is one of the classical hallmarks of apoptosis; at early stage of 
apoptosis PS flips from the inner leaflet of plasma membrane to the exterior. Annexin 
V interacts with PS in a calcium dependent manner, which is the basis for the assay. 
So fluorescent substrate conjugated Annexin V could be used to detect PS positive 
alive cells, whereas PI is used to exclude cells with compromised plasma membrane, 
for instance, necrotic cells. In (Figure 9), PS exposure was observed in Jurkat cells 






Figure 8. Raji cells were resistant to etoposide treatment. Cell viability was 
determined by MTT assay. Raji cells (0.8 million cells in 1ml medium) were 




















































Figure 9. Raji cells failed to expose phophatidyl serine upon etoposide
treatment. Annexin V+ PI staining after Raji and Jurkat cells were treated with 
different doses of etoposide (5, 10 and 40μM) for 12hrs. Jurkat cells showed 
higher percentage of Annexin V+ cells both in early and late apoptosis events. 












rather late apoptotic or necrotic cells, shown as both Annexin V and PI positive 
population. No detectablePS was exposed in Raji BL cells. To minimize the 
possibility of necrotic cells, 10μM etoposide was chosen for these studies.  
Another feature of apoptosis is caspases activation. Therefore, caspase-3, -9 and -8 
activations were compared in Raji and Jurkat cells. Exposure of Raji B cells to 
etoposide resulted in minimal caspase-3 (only 1-2 times higher than control cells), 
whereas a much stronger activation (8-9 times higher than untreated cells) was 
detected in Jurkat cells. No detectable caspase-8 or -9 activities were found in Raji 
cells. One of the caspase-3 substrates, the DNA repair enzyme PARP was not cleaved 
in etoposide treated Raji cells. However, the active caspase-3 mediated cleavage of 
PARP (p85) was observed in treated Jurkat cells (Figure 10). In conclusion, Jurkat 
cells were sensitive to etoposide induced apoptosis, whereas, Raji cells were resistant 
to etoposide. Similar results were obtained with other chemotherapeutic drugs, 
namely taxel, daunorubicin and 5-Aza. One of the well known mechanisms of 
chemoresistance as described in introduction is overexpression of anti-apoptotic 
protein, Bcl-2 in tumor cells. However, compared to Jurkat cells, relatively lower Bcl-
2 protein level was observed in Raji cells as shown in (Figure 11). Hence, in general, 
Raji cells are resistant to chemotherapeutic drugs-induced caspases activation and cell 
death and this resistance is not a function of increased Bcl-2 expression. 
  
1.2. BL cell lines are resistant to etoposide-induced caspase activation both in 
vivo system and in cell free system 
Based on the results from the Raji cell line, other BL-derived cell lines were tested for 
























Figure 10. Raji cells were defective in caspase activation as indicated. A,B, 
Caspase-3, 8 and 9 activities were shown in Jurkat and Raji cells respectively after 
treatment with 10μM etoposide and 25μM zVAD as indicated after 16hrs. Folds 
increase was evaluated by treated cells compared to untreated cells. C, PARP 
cleavage (85Kd) band shown on western blot is an indication of active caspase-3 









































Figure 11. Quantification of CD95 and Bcl-2 expression in Raji and Jurkat
cells. One million Raji and Jurkat cells were stained with specific primary 
antibody as indicated, and followed with secondary antibodies with FITC 
conjugation. After immunostaining, cells were analyzed by FACS flow cytometry. 
Raji cells showed higher CD95 but lower Bcl-2 level compared to Jurkat T cells. 




































































































Figure 12. BL cells were resistant to etoposide. Panel of BL-derived cell lines 
were exposed to chemotherapeutic drug- etoposide for 24hrs and 48hrs as 
indicated. Percentages of cell death for 24hrs and 48hrs treatment were assessed 
by PI incorporation and Hoechst Staining respectively. 
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negligible apoptosis at early (24hr) or late (48hr) time points (Figure 12). Late 
apoptosis was observed in Ramos and Mutu I cells (around 30% and 70% 
respectively); however, there was no early apoptosis detected in this cell line. 
Although more sensitive than other BL cell lines, Mutu I still responded less to 
etoposide than Jurkat T leukemic cells. DEVD-AMC cleavage (indicative of caspase-
3 activation) was also significantly reduced in all BL cell lines tested, when compared 
to Jurkat cells (Figure 13). Moreover, no activation of caspase-9 could be detected in 
BL cells upon etoposide treatment. To confirm these results, cytosolic extracts were 
immunoblotted with specific antibodies against caspse-3 and caspase-9. Etoposide-
triggered processing of pro-caspase-3 into the p20 fragment and the p17 active 
subunit was readily detected in Jurkat cells (Figure 13). Concomitant processing of 
pro-caspase-9 into its characteristic p35 fragment was also seen; moreover, a p37 
fragment of caspse-9, known to be generated by caspase-3, was also evident in Jurkat 
extracts. However, no processing of pro-caspase-9 was seen in BL cell extracts, with 
the exception of Rael, in which the p35/p37 bands could be detected. Processing of 
pro-caspase-3 was also absent in most BL cell lines, although some evidence of 
p20/p17 subunits was consistently seen in Rael, and partial processing to the p17 
fragment was observed in Ramos. Taken together, these results demonstrated that 
resistance to etoposide-induced activation of caspases is a common feature of BL cell 
lines. This general resistance was not only seen at the cell level, but also when S-100 
cytosolic fractions from these cell lines were incubated with cytochrome c and dATP 
(to trigger apoptosome formation) (Figure 16). 
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Figure 13. Defective caspases activation in BL cells. Caspase-3 activation and 
caspase-3 /-9 processing in panel of BL derived cell lines after treatment with 10μ
M etoposide for 12hrs. Jurkat cells were used as positive control. 
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Etoposide triggers mitochondrial release of cytochorme c in cancer cells, resulting in 
activation of the caspase cascade and induction apoptosis (Robertson et al., 2000). To 
further delineate the apoptosis defect in BL cells, we tested whether etoposide 
treatment of Raji cells could induce mitochondrial alteration. Raji cells were chosen 
for these experiments because they serve as a prototypic example of chemoresistant 
BL-derived cell line, and are widely used in lymphoma studies. As seen in (Figure 14), 
etoposide triggers a dissipation of the ∆ψm and mitochondrial release of cytochrome c 
both in Jurkat and Raji cells (Figure 15). Therefore, defective activation of caspase-9 
and caspase-3 in the Raji cell line is not due to the absence of cytochrome c release. 
Cell free system of S100 cytosol was then used to further evaluate whether BL-
derived cell lines were capable of promoting Apaf-1-dependent activation of caspases. 
To this end, exogenous cytochrome c was added to S-100 cytosolic extracts derived 
from the six BL cell lines. Cytochrome c and dATP were shown to activate caspase-9 
and -3 by promoting apoptosome formation in the cell free system of apoptosis. Jurkat 
cell extracts served as a positive control. Caspase-3 processing was readily detected in 
Jurkat cells, whereas activation of pro-caspase-3 was observed neither in Raji cells, 
To further confirm that cytochrome c release is not only limited in etoposide triggered 
mitochondria perturbation, Raji cells, were also exposed to protein kinase inhibitor, 
staurosporine and proteasome inhibitor, lactacystin. Staurosporine is known to 
directly target the mitochondria and induce cytochrome c release, while proteasome 
inhibitor lactacystin induced mitochondria-dependent cell death was found in other 
cell types (Johansson et al., 2003; Pasquini et al., 2000). As shown in figure 15, 
cytochrome c could also be released by these two stimuli. Furthermore, the release of 
cytochrome c from the mitochondria could not be blocked by general caspases 






Figure 14. Etoposide induced mitochondria changes in Raji cells. Intrinsic 
early apoptotic mitochondria transmembrane (∆ψm) potential dissipation was 
evaluated by TMRE staining. One million Raji or Jurkat cells were stained with 
TMRE after exposure to 10μM etoposide, and stained cells were balanced in 
HEPES buffer with the same amount of TMRE and run on FACS flow cytometry. 
Dissipation of ∆ψm is shown as drop in FL3-H fluorescent intensity. CCCP was 








sensitize mitochondria to release cytochrome c, thus indicating that chemoresistance 
in Raji cell line might be due to a defect in apoptotic signaling downstream of the 
mitochondria.  
 
1.4 Subthreshold levels of Apaf-1 in the cytosol of human BL cells 
Silencing of Apaf-1 has previously been reported in certain melanoma- and leukemia- 
derived cell lines (defective apaf-1 expression). To explore whether chemoresistance 
in BL cells could be explained by defective Apaf-1 expression, we performed 
immunoblotting with specific antibodies against Apaf-1 in our panel of BL cells. 
When cytosolic extracts of Jurkat cells were compared to extracts from apoptosis-
resistant BL cell lines, a marked reduction of Apaf-1 was observed, most notably in 
Raji cells (Figure 18). However, Apaf-1 was found to be present at comparable levels 
in total cell extracts of Jurkat and Raji cells, suggesting that subcellular 
compartmentalization of Apaf-1 differs between the two cell lines. Indeed, 
approximately 80% of Apaf-1 was present in the cytosol in Jurkat cells, whereas only 
30% of total cellular Apaf-1 was recovered in the cytosol of the Raji cell line (Figure 
18). Hence, it appeared that caspase activation in Raji cells might be hampered by a 
subthreshold level of cytosolic Apaf-1. Of note, the sequence analysis of Apaf-1 
mRNA in Raji cells disclosed two previously reported mRNA species (corresponding  
to Apaf-1 isoforms with and without an extra WD40 repeat in the COOH terminal 
domain) (Benedict et al., 2000); however, no sequence anomalies were found. Hence, 
the ectopic subcellular localization of Apaf-1 in these cells could not be explained by 
alternative (mutated or deleted) forms of Apaf-1.  
 





Figure 16. Exogenous cytochrome c failed to induce caspase-3 activation in 
S100 cytosols from BL cells. S100 cytosol were collected from panel of BL cells, 
and incubated with 1mM dATP and 4μM cytochrome c for 30min at 30℃. 
Caspase-3 activation and processing were shown as active processed p17 form in 
A and DEVD-AMC pmol/min release in B. Jurkat S100 cytosol was used as 
positive control.
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Figure 17. Wide type caspase-3 could be cleaved independent of apoptosome
in BL cell lines. Granzyme B could cleave caspase-3 and activate caspase-3 like 
proteases in S100 cytosol from BL cells. 60μg of the S100 fraction from panel of 
BL cells were collected and treated with 2U recombinant granzyme B to induce 
caspase activation. Active caspase-3 processed form (p17) is shown in A, and 
caspase-3 substrate DEVD-AMC cleavage is shown in B. Jurkat S100 was 









To test whether the decreased level of cytosolic Apaf-1 precluded apoptosome 
formation, size exclusion chromatography was used to fractionate cytosolic extracts 
from Jurkat and Raji cells. After activation with cytochrome c to induce Apaf-1 
oligomerization, or a similar treatment in the absence of cytochrome c as a control, 
fractions separated by gel filtration chromatography were analyzed for Apaf-1 using 
specific antibodies. Control samples from both cell lines demonstrated Apaf-1 elution 
in fractions corresponding to approximately Mr 150,000, consistent with the 
monomeric form of this protein (Figure 19, 20). As expected, incubation of Jurkat 
extracts with exogenous cytochrome c yielded a shift in the Apaf-1 elution profile 
such that the majority of Apaf-1 appeared in fractions corresponding to Mr 700,000- 
2,000,000 (Figure 19). No such shift was discernible in Raji cell extracts treated with 
cytochrome c (Figure 20), suggesting that Apaf-1 oligomerization is defective in Raji 
cell cytosolic extracts.  
Caspase-9 becomes activated in the apoptosome complex (Acehan et al., 2002); 
moreover, a diminished amount of caspase-9 in the apoptosome was previously linked 
to a reduced susceptibility of ovarian cancer cells to cisplatin- triggered apoptosis (Liu 
et al., 2002). As seen in Figure 20, defective apoptosome activation in Raji cells was 
associated with negligible amounts of active caspase-9 in the Apaf-1-containing 
fractions. In contrast, after cytochrome c-dependent activation of Jurkat cytosolic 
extracts, a significant amount of pro-caspase-9 was processed into the active p35/p37 
subunits (Figure 19). Hence, defective cytosolic expression of Apaf-1 in Raji BL cells 
is associated with the absence of apoptosome formation and, consequently, with a 
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Figure 19. Apoptosome formation in Jurkat cells. Apaf-1 oligomerization in 
Jurkat T cells S100 cytosol was initiated by dATP and cytochrome c. dATP and 
cytochrome c treated Jurkat S100 cytosol (2 mg) was loaded on Sephacryl S-300 
gel filtration column to fraction different sizes of proteins in the cytosol. Samples 
were collected in different fractions and then loaded on SDS-Page for western blot 
to detect Apaf-1 and caspase-9 distributions in the fractions as indicated. 
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Figure 20. Defective apoptosome formation in Raji cells. Apaf-1 
oligomerization is defective in Raji cells S100 cytosol triggered by dATP and 
cytochrome c. 2mg of Raji S100 cytosol treated with dATP and cytochrome c was 
loaded on Sephacryl S-300 for gel filtration. Samples were collected in different 
fractions and then loaded on SDS-Page for western blot to detect Apaf-1 and 
caspase-9 distributions in the fractions as indicated. 
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1.6 Overexpression of Apaf-1 restores sensitivity to apoptosis in the Raji BL cell 
line 
To test whether enhanced levels of Apaf-1 in the cytosolic compartment could 
sensitize BL cells to apoptosis, Apaf-1 was stably over expressed by stable 
transfection of pCDNA3.1Apaf-1 plasmid into Raji cells. Increased Apaf-1 expression 
was detected in total cell extracts prepared from the transfectants when compared with 
extracts from vector controls. Furthermore, Apaf-1 expression was increased in the 
cytosolic fraction of the transfected Raji cells (Figure 21). Apaf-1-overexpressing Raji 
cells were considerably more sensitive to etoposide-induced apoptosis as compared to 
mock-transfectants (Figure 22). Moreover, sensitivity to staurosporine, another 
apoptotic agent that targets the mitochondria pathway (Samali et al., 1999), was also 
significantly enhanced. In concordance with these findings, both etoposide and 
staurosporine triggered robust activation of caspase-3 and increased apoptosis in 
Apaf-1-overexpressing cells, whereas their mock-transfected counterparts remained 
resistant (Figure 22). As seen in Figure 23, enforced expression of Apaf-1 also 
potentiated caspase-3 activation in S100 extracts in response to exogenous 
cytochrome c to levels comparable to the Jurkat cytosols. Raji cells harbor wild type 
Apaf-1 (discussed above), and it therefore remains to be determined why transfected, 





















































Figure 22. Overexpression Apaf-1 sensitized Raji cells to etoposide and 
staurosporine. A, Apoptotic cells were evaluated by accumulation of subG1 cells 
upon treatment with 1μM staurosporine and 10μM etoposide for 48hrs. B, 
Caspase-3 like proteases activity is shown by DEVD-AMC cleavage after 10μM 



























Figure 23. Overexpression of Apaf-1 sensitizes the S100 cytosol of Raji cells to 
dATP and cytochrome c induced caspase activation. Apoptosis in Raji S100 
cytosol by cytochrome c is shown as increased caspase-3 activity in RajiApaf-1
cells. 
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could perhaps be a consequence of a supra-normal level of expression of Apaf-1 in 
the former case. Our data nonetheless demonstrate that re-expression of Apaf-1 in the 
cytosol renders Raji BL cells susceptible to cytochrome c-dependent caspase 
activation. Of note, over-expression of Apaf-1 sensitized cell death to both 
staurosporine and etoposide and this occurred at rather late time points, 48hrs. 
 
2. Plasma membrane sequestration of Apaf-1 contributes to BL cells resistance to 
etoposide and staurosporine-induced apoptosis 
2.1 Plasma membrane sequestration of Apaf-1 in chemoresistance BL cells 
Apaf-1 has been reported to reside exclusively in the cytosol (Hausmann et al., 2000), 
although other studies have suggested that the subcellular localization of Apaf-1 is 
cell type-dependent; indeed, overexpression of Bcl-2 in a murine B lymphoma cell 
line was shown to trigger redistribution of APaf-1 from the Golgi apparatus to a 
perinuclear compartment (Ruiz-Vela et al., 2001). To investigate the subcellular 
distribution of Apaf-1 in Raji cells, co-localization studies were performed using 
specific markers targeting to the nucleus, Golgi apparatus, and mitochondria 
respectively. Confocal microscopic analysis did not provide any evidence of Apaf-1 
localization in these subcellular compartments in Raji cells or in Jurkat cells (Figure 
24). Moreover, no alterations in the distribution of endogenous Apaf-1 were observed 
upon etoposide treatment of these cell lines. However, Apaf-1 in Raji cells appeared 
to be closely associated with the plasma membrane. In fact, confocal analysis of 
different x-y planes along the z axis of individual cells suggested the aggregation of 










Figure 25. Plasma membrane sequestration of Apaf-1 in BL cells. (A) Merged 
image of 10 consecutive cross-sections of 1 representative Jurkat cell labeled with 
Apaf-1–specific antibodies. (B) Representative cross-sections of Apaf-1–labeled 
Raji cells are displayed in the large panels, whereas several optical sections of 
each cell were merged in the small panels to generate images in the x-z and y-z
axes, respectively. Note the overlay between Apaf-1 (green) and the lipid raft




Lipid rafts are sub-domains of the plasma membrane that are enriched in 
sphingolipids in optimal admixture with cholesterol (Simons and Toomre, 2000). To 
test the hypothesis that Apaf-1 could be associated with lipid rafts, Raji cells were 
labeled with cholera toxin B (CTB), a well-known marker of such microdomains. Co-
staining of cells with antibodies specific for Apaf-1 revealed a substantial overlap 
between the lipid raft signal and Apaf-1 (Figure 25). No such overlap was observed in 
Jurkat cells. To obtain further evidence for lipid raft association, Raji cells were 
treated with the cholesterol-depleting reagent, methyl-beta-cyclodextrin (MCD), that 
is known to disrupt lipid rafts and caveolae. As seen in Figure 26, Apaf-1 was 
dispersed in the cytoplasm upon MCD treatment, and the co-localization with CTB 
became less evident. The pattern of Apaf-1 distribution in Jurkat cells, however, 
remained unchanged (Figure 27). Importantly, S100 cytosolic extracts prepared from 
MCD treated Raji cells supported cytochrome c- dependent activation of caspase-3, 
while control extracts failed to do so (Figure 28). MCD treatment of Jurkat cells, on 
the other hand, did not significantly affect apoptosome-driven caspase activation.  
Recent studies have shown that lipid raft domains interact with (and are anchored to) 
the underlying actin cytoskeleton (Oliferenko et al., 1999). We therefore assessed 
whether manipulation of the cytoskeleton might affect Apaf-1 distribution in the Raji 
BL cells. To this end, cells were treated with cytochalasin B (CB), a fungal metabolite 
that prevents actin polymerization and promotes disruption of the microfilament 
network. CB triggered a redistribution of Apaf-1 in Raji cells, similar to that observed 
in MCD-treated cells (Figure 26).  Moreover, cytosolic extracts from CB-treated Raji 
cells were also able to promote cytochrome c-dependent caspase activation (Figure 
28). Again, no significant effects were observed in Jurkat cells. Together, these results 





Apaf-1 CT B Merge
Figure 27. Defective of Apaf-1 redistribution by MCD in Jurkat cells. Apaf-1 
distribution pattern was not changed in MCD treated Jurkat cells. Jurkat cells 
treated with 100mM MCD were collected for costaining with CT B (red) and 
































Figure 28. Mobilization of plasma membrane associated Apaf-1 sensitized 
Raji cells S100 cytosol to apoptosis. Raji and Jurkat S100 treated with 5μM CB 
or 100mM MCD for 1hr were incubated with dATP and cytochrome c. Caspase-3 
like proteases activity were analyzed by DEVE-AMC cleavage. 
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membrane of the Raji BL cell line, and indicate that Apaf-1, upon mobilization from 
these membrane domains, is capable of supporting cytochrome c-dependent caspase 
activation in the cytosol.  
 
2.2 Reversal of chemoresistance in human BL cells upon liberation of Apaf-1 
Finally, we were interested in determining whether mobilization of constitutive Apaf-
1 could restore sensitivity of BL cells to chemotherapeutic agents. To test this, Raji 
cells were pretreated with a low dose of MCD, insufficient by itself to trigger cell 
death, and then subjected to etoposide treatment. As seen in Figure 29, MCD 
sensitized the Raji BL cell line to etoposide-induced apoptosis, in a time-dependent 
manner. Similar results were obtained in the chemoresistant BL-derived cell line, 
DG75 (Figure 29). The Mutu I cell line, on the other hand, in which partial post-
mitochondrial caspase activation is evident, was not sensitized further upon pre-
incubation with MCD (data not shown). While other concurrent effects of MCD-
mediated lipid raft disruption in BL cells could not be excluded, these results are 
consistent with the view that MCD treatment triggers Apaf-1 relocalization to the 
cytosolic compartment, thus allowing for etoposide-stimulated, apoptosome-driven 
apoptosis of otherwise resistant cancer cells.  
 
3. The role of IAPs and Smac in chemoresistant BL cells 
 
In the first part, subthreshold cytosolic Apaf-1 due to plasma membrane sequestration 
contributes to chemoresistance of BL cell lines. Therefore, restoring cytosolic Apaf-1 
by either stable overexpression (the total cellular level) or lipid raft mobilized plasma 



































































Figure 29. MCD sensitized BL cells to etoposide induced apoptosis. Pretreat BL 
Raji (A) and DG75 (B) cells with 100mM MCD for 1hr, then exposed to 10μ M 
etoposide for 24hrs and 48hrs. Cells were collected and stained with DNA specific 
dye Hoechst. Apoptotic cells were counted from three independent experiments.  




etoposide, and mitochondrial targeting reagent, staurosporine. However, compared to 
the sensitive cell line, Jurkat, these manipulations could only sensitize BL cells to 
apoptosis at rather late time points, 48hrs and 72hrs (Figure 22 and 29). The question 
thus arises as to why restored cytosolic Apaf-1 could not induce prompt apoptosis in 
BL cell lines. Thus, the expression profile of another known anti-apoptotic protein 
family, IAPs, was compared in Raji and Jurkat cells.  
 
3.1 IAPs are highly expressed in BL-derived cell lines, and serve to modulate 
apoptosis in these cells in an apoptosome-dependent manner 
 
As seen in Figure 30, the expression of cIAP2 was elevated in Raji cells compared to 
the Jurkat cell line. Similar findings were obtained in several other BL-derived cell 
lines. Depleting cytosolic cIAP2 by immunoprecipitation using specific cIAP2 
antibodies was performed to observe its impact on cell free cytosolic apoptosis. 
However, immunodepleted cellular extracts remained refractory to cytochrome c-
dependent caspase activation (Figure 31).  These findings stimulated us to investigate 
whether elevated cIAP2 delayed the response of BL cells to apoptotic stimuli, thus 
cIAP2 was immunodepleted from wild type Raji cells. However, these cells were not 
sensitized to cytochrome c/dATP-dependent activation of caspases. Then, we tested 
whether immunodepletion of IAPs in BL cells expressing Apaf-1 in the cytosolic 
compartment could sensitize these cells further to apoptosis. To this end, 
immunoprecipitation of cIAP2 was conducted in Apaf-1- versus mock-transfected 
Raji cells using specific antibodies (Figure 32 and 33), and the resulting cytosolic 
extracts were assessed for cytochrome c- dependent activation of caspases. As 
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Figure 31. Immunodepletion of cIAP2 could not sensitize Raji S100 cytosol to 
cytochrome c and dATP induced caspase activation. A, cIAP2 was 
immunodepleted with specific primary antibody in both Jurkat and Raji cells. 
30μg protein was loaded in each sample. The arrows indicated two bands 
recognized by anti-cIAP2 antibody, p68 is cIAP1 and p66 is cIAP2. However, 
only cIAP2 could be precipitated by the anti-cIAP2 antibody. Bcl-2 antibody was 
used as control B, Incubated Raji and Jurkat cells S100 after immunodepletion of 
cIAP2 with dATP and cytochrome c, followed with DEVD-AMC cleavage assay 
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Figure 33. Immunodepletion of cIAP2 sensitized Raji S100 cytosol to dATP
and cytochrome c in RajiApaf-1 cells. S100 cytosol from RajiVec or RajiApaf-1
cells were immunodepleted cIAP2 and then incubated with dATP and cytochrome
c. Caspase 3 like proteases activity were shown as DEVD-AMC pmol release 
along with time relapse as indicated. ▲ control,  treated with dATP and 
cytochrome c
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expressing cells. Moreover, immunodepletion of cIAP2 served to potentiate caspase 
activation only in Raji/Apaf-1 cells, but failed to do so in the mock transfectants 
which was similar as in wild type Raji cells (Figure 32 and 33).  Together, these 
findings support that, at least in cell free systems, cIAP2 serves to modulate apoptosis 
in the presence of a functional apoptosome.  
 
3.2 Smac release is defective in BL-derived cell lines: introduction of cell-
permeable Smac N7 peptides potentiate Raji cells to apoptosis in an Apaf-1-
dependent manner 
 
Since high levels of IAPs were found in BL cells, cytosolic Smac, a protein that 
antagonizes IAPs, was studied in the chemoresistant Raji cell. Raji cells were treated 
with staurosporine, and the amounts of Smac and cytochrome c in the cytosolic 
fraction were determined (Figure 34). Jurkat cells were included as a control. 
Evidence of cytochrome c release from mitochondria was obtained; however, Smac 
release was low or absent in Raji cells. Control experiments revealed that the total 
amount of Smac was similar in Jurkat and Raji cells (Figure 34).  Moreover, whereas 
the mitochondrial fraction of Smac gradually decreased in Jurkat cells, no significant 
decrease was observed in Raji cells following staurosporine treatment, thus 
suggesting that Raji cells were defective in inducing Smac release.  
Several groups have shown exogenous N-terminal Smac peptides may potentiate 
apoptosis of cancer cells (Arnt et al., 2002; Fulda et al., 2002; Jia et al., 2003). To 
circumvent the apparent defect in mitochondrial Smac release in Raji cells, and in 
order to test whether the modulation of IAPs may serve to sensitize these cells to 











of staurosporine (Figure 35). Mock transfectants were utilized as a control. The 
incubation of Apaf-1-transfected cells with staurosporine resulted in a moderate 
degree of apoptosis at early timepoints (16hrs). Co-incubation of these cells with 
Smac peptides and staurosporine resulted in a 3-fold higher level of apoptosis (Figure 
35). Smac N7 peptide had no effect in the mock-transfected cells. Pre-incubation of 
cells with the pan-caspase inhibitor, zVAD-fmk, abrogated the Smac-induced 
potentiation of apoptosis.  
Proteasome inhibitors have been reported to trigger apoptosis in cancer cells 
(Rajkumar et al., 2005), although the underlying signaling pathways remains 
incomplete. To test whether the role of Apaf-1 is confined to staurosporine, Raji/Apaf-
1 or Raji/Mock cells were treated with lactacystin, a specific proteasome inhibitor. As 
seen in Figure 35, lactacystin also yielded a moderate level of apoptosis in cells over 
expressing Apaf-1, but not in the mock-transfected counterparts. Moreover, the 
addition of Smac peptides resulted in a 3-fold higher level of apoptosis in Raji/Apaf-1 
cells. Again, apoptosis was found to be caspase-dependent. As a control experiment, 
cytosolic extracts from Apaf-1- and mock-transfected Raji cells were subjected to 
immunoblot analysis. Apaf-1 was over-expressed, as expected, in the cytosol of the 
stably transfected cell line; however, there were no differences in the level of IAPs 
expression between Apaf-1- and mock-transfected cells (Figure 35).  Of note, Smac 
peptides sensitized Raji/Apaf-1 to both staurosporine and lactacystin treatment at early 
time points, 12hrs and 16hrs respectively.  Hence, the effect of Smac peptides in our 
model appeared related to the expression of Apaf-1 per se, and not to a compensatory 
decrease of IAPs following the stable overexpression of Apaf-1.  
 
4. Other apoptotic inhibitors in BL cell lines 
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The apoptosis signaling pathway was carefully studied in Raji cells. By further 
dissection of other BL-derived cell lines, evidence for different mechanisms of 
apoptosis resistance was obtained. As discussed in introduction, the role of 
apoptosome formation could be retarded by plasma membrane sequestration of Apaf-
1. And also from our and others data, apoptosome activity could be modulated by 
introduction of cytosolic Smac. Furthermore, a number of recent studies have 
discovered that other proteins could modulate apoptosome formation and activation 
by targeting different aspects in cell death pathway. These related inhibitors were 
documented as IAPs targeting and inhibiting caspase activation, while Hsps functions 
as the inhibitor of apoptosome formation by interfering cytochrome c and Smac 
release, or Apaf-1 oligomerization (Chauhan et al., 2003; Paul et al., 2002; Saleh et al., 
2000). Based on these studies, the impacts of these inhibitors on mitochondria 
dependent cell death were investigated in BL derived cell lines.  Bcl-2, Hsp27, Hsp70 
and IAPs protein expression were screened in a panel of BL cell lines by western blot 
(Figure 36 and 37). In general, IAPs and Hsp70 were highly expressed in these cell 
lines, especially cIAP2 was highly expressed in most BL cell lines except Mutu III. 
Including Jurkat cells as control, there was no difference in Hsp70 level. Furthermore, 
the expression levels followed with staurosporine and lactacystin were studied. Both 
cIAP2 and XIAP levels were decreased in staurosporine treated cells, however no 
obvious change was detected upon lactacystin treatment. However there was no cell 
death detected under these conditions. Therefore, the initiation of apoptosis in these 
two cell lines, at least, does need Apaf-1 and complete apoptosome function. Without 











however cells still could not be sensitized.  Another interesting finding was the 
comparative expression pattern of Bcl-2 and Hsp27 (Figure 36). The cells with Bcl-2 
expression showed defective Hsp27 expression. In Ramos and DG75 cells, Hsp27 
were higher expression than others, however, Ramos showed negligible and DG75 
showed moderate Bcl-2 expressions compared to the other Hsp27 negative cell lines. 
DG75 cells, in particular, were completely resistant to all apoptotic stimuli used in 
these studies, and showed both Bcl-2 and Hsp27 expression. Staurosporine could 
almost completely inhibit Hsp27 expression in DG75 but not in Ramos cells. There 
was no difference after lactacystin treatment. In contrast to staurosporine, lactacystin 
showed no effect on IAPs and Hsp27 expression. This could be due to the inhibition 
of proteasome function by lactacystin which could therefore block the degradation of 
these proteins (Figure 36 and 37). These findings led us to ask the question whether 
these cell lines could be sensitized to apoptosis after silencing or down-regulation of 
Hsp27 levels.  
Therefore, Hsp27 antisense was used to investigate its role on potentiation of 
apoptosis in BL cells. However, results showed that after down regulation of Hsp27 
protein levels to nearly 50% in both DG75 and Ramos cells (Figure 38), neither cell 
line showed any response to apoptotic stimulation upon exposure to etoposide and 
staurosporine. Therefore, Hsp27 alone is unlikely to be a determinant of apoptosis 
sensitivity in these cells. Future studies on Bcl-2 and Hsp27 silenced in combination 
(in the DG75 cell line) may be interesting to pursue. 
 
5. Alternative apoptotic pathway in BL cells 
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Even though staurosporine or lactacystin showed varying influence on anti-apoptotic 
proteins (Figure 36, 37), when the basic cell death was studied in these BL-derived 
cell lines, cells exhibited different death sensitivities. Ramos and Mutu I, in contrast 
to Raji and DG75 cell, were highly sensitive to staurosporine and lactacystin 
treatment by Hoechst staining (Figure 39). Interestingly, lactacystin induced apoptosis 
in Ramos cells could not be blocked by general caspases inhibitor, zVAD (Figure 39). 
However in Mutu I cells, zVAD significantly blocked cell death. These results 
indicate that lactacystin induced apoptosis in Ramos cells was not caspase dependent. 
This was further confirmed by using Annexin V and PI staining (Figure 42, 43).  
Upon exposure of cells to staurosporine or lactacystin alone, the early apoptosis were 
38% or 24% respectively as shown in Annexin V (+)/ PI (-) population and the late 
apoptosis were 40% or 32% respectively as shown in Annexin V (+)/ PI (+) 
population in Annexin and PI double staining windows (Figure 42). However, in 
zVAD pretreated Ramos cells, the early apoptosis was decreased to 21% or 7% 
respectively and late apoptosis was increased to 56% or 45% respectively. But there 
was no difference in total apoptosis population when pretreated with zVAD. In 
conclusion, zVAD could not block cell death by staurosporine or lactacystin in Ramos 
cells (Figure 42).  However, zVAD completely blocked cell death in Mutu I cells 
under the same conditions (Figure 43). This raised the question if caspase independent 
cell death was mitochondria dependent or not in Ramos cells.  
To this end, cytochrome c and Smac release were observed in BL derived cell lines 
after exposure to staurosporine, since these molecules are modulators of caspases 
activation. As shown in Figure 40 and 41, Smac release was defective in DG75 and 
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Figure 38. Transient transfection of antisense Hsp27 silenced Hsp27 
expression to 50% in DG75 cells. A, Statistic data from ImageGuage to quantify 
Hsp27 expression from the bands of western blot. Samples 1-2 and 3-12 were 
transfected with mock and antisense Hsp27 cDNA, respectively, with different 
amount of DMRIE-C and DNA as indicated. The transfection efficiency was 
calculated by comparing the area under the indicated curve. B, Samples from 1,2 
and 11,12 respectively were run for western blot to detect Hsp27 expression. Bcl2 
was used as endogenous transfection control. 
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Figure 39. BL derived cell lines showed different sensitivities to staurosporine
and lactacystin induced cell death. A, BL cells were treated with 10μM 
lactacystin or 1μM staurosporine for 24hrs. Cells were then collected to evaluate 
percentage of cell death by Hoechst 33342 staining. B, Pre-incubation of Ramos 
and Mutu I cells with 25μM general caspases inhibitor, zVAD, blocked cell death 











Figure 42. Lactacystin and staurosporine induced caspase independent cell 
death in Ramos. Ramos cells were treated with 1μM staurosporine or 10μM 
lactacystin as indicated. Pre-treated Ramos cells with 25 μM zVAD could not  
block cell death. Cell death was characterized as PS positive cells by Annexin V 
and PI staining by FACS flow cytometry. Percentage of each population is shown 
























Figure 43. Lactacystin and staurosporine induced caspase dependent 
apoptosis in Mutu I cells. Mutu I cells were treated with lactacystin and 
staurosporine as indicated. 25μM zVAD was used to pretreat cells to inhibit 
lactacystin and staurosporine induced cell death, shown as PS positive cells by 
Annexin V and PI staining. 
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Mutu I cells, Smac release were found in both cases. Cytochrome c release showed a 
similar pattern, however in Raji cells, cytochrome c could be detected whereas Smac 
release was defective suggesting that in Raji cells, cytochrome c and Smac release 
could be controlled by different mechanisms. In DG75 cells, there is no cytochrome c 
or Smac release found after staurosporine treatment. Small molecules released from 
mitochondria have been shown to initiate and potentiate caspases activation which 
eventually overwhelms cells to apoptosis. But this seems not to be true at least in 
Ramos cells since the cell death might not be caspases dependent even though both 
cytochrome c and Smac were released from mitochondria. Because zVAD could not 
block cell death in Ramos cells, it was further questioned if zVAD could block 
cytochrome c and Smac release in Ramos cells. As shown in Figure 41, zVAD 
blocked Smac release but not cytochrome c release in Mutu I cells, which indicated 
that in Mutu I cells cytochrome c release was not caspases dependent while Smac 
release was. This is coordinate with previous findings. In Ramos cells, zVAD blocked 
partial Smac release, but did not inhibit cytochrome c release. Mitochondria 
transmembrane potential were also studied in both staurosporine and lactacystin 
treated Ramos cells (Figure 45). Compared to Mutu I cells showing dramatic 
dissipation of ∆ψ by staurosporine, no detectable drop of ∆ψ could be evidenced in 
Ramos cells. And there was no drop of ∆ψ in lactacystin induced cell death in Ramos 
cells. So in conclusion, both caspase dependent and independent cell death were 
found in Ramos cells. Furthermore, it is caspase independent cell death that played a 














Figure 45. Defective dissipation of mitochondria trans-membrane potential in 
Ramos cells upon treatment with lactacystin and staurosporine. Mutu I and 
Ramos cells were treated as indicated. Cells were then collected for TMRE 
staining for detection of mitochondria transmembrane potential. There was less or 




1. The role of the apoptosome in controlling the sensitivity of cancer cells to 
chemotherapeutic agents 
 
In the present study, BL-derived cell lines are shown to be deficient in apoptosome-
dependent activation of caspases, downstream of mitochondria. The data obtained in 
the Raji cell model show that the defective activation is linked to a lack of expression 
of Apaf-1 in cytosolic compartment (Figure 46). This is the first time that aberrant or 
ectopic Apaf-1 localization has been described as a mechanism for chemoresistance in 
cancer cells. Transfection of Apaf-1 to resistant Raji cells yielded elevated levels of 
Apaf-1 in the cytosol and conferred sensitivity to apoptosis induced by etoposide and 
staurosporine, thus providing direct evidence that Apaf-1 is an important determinant 
of cytochrome c-dependent apoptosis in these cells. Therefore, Apaf-1 localization is 
a key issue in the present study. By comparing Apaf-1 homologue in different species, 
Apaf-1 structure is clarified. However, is Apaf-1 localization also comparable in 
mammals and other species? And does the different localization contribute to 
modulating apoptosome activity in cells fateful to apoptosis?   
From nematodes to mammals, the conserved apoptosome complex functions to 
activate and initiate caspases during so-called mitochondria-dependent apoptosis. 
Auxiliary components of the apoptosome machinery could be different in different 
species; however, Apaf-1 or its homologue are the conserved key molecules both in 
nematodes (CED-4), and in the fruit fly (Dark/Dapa1/DREDD) (Danial and 
Korsmeyer, 2004). However a thorough analysis of the structure of CED4 and Apaf-1 
















Figure 46. Schematic model of mechanism of chemoresistance in Raji cells.
The model shows the apoptosis defect in BL-derived Raji cells, and the putative 
mechanism whereby lipid raft disruption sensitizes these cells to etoposide-
induced killing. MCD, methyl-β-cyclodextrin. 
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cells, Apaf-1 assumes an auto-inhibitory conformation by auto-interaction from 
different domains. Therefore its CARD domain responsible for recruiting caspase-9 
fails to interact with CARD from caspase-9; the auto-inhibitory function somehow in 
mammals was found different from the Apaf-1 homologue CED-4 in C-elegance. In 
vivo analyses of C.elegans have further demonstrated that CED-4 is normally 
sequestered and the caspases activation function therefore is inhibited by the anti-
apoptotic protein CED-9 (a homologue of Bcl-2) on the mitochondria. Over-
expression of the ‘BH3-only’ protein EGL-1 (Conradt and Horvitz, 1998; Yan et al., 
2004) releases CED-4 from CED-9. Released CED-4 could also oligomerize and 
induce dimerization of CED-3. The purified CED-4 protein spontaneously forms large 
homomeric complexes in solution. Predictions based on structural similarities to other 
proteins have suggested that CED-4 upon ATP-binding forms homohexamers 
(Seiffert et al., 2002). So the modulation of CED-4 function in nematodes mainly 
depends on the interaction with CED-9. This could be due to CED-4 lack of WD40 
domains as in mammals or Drosophila.   
However, in mammals, Apaf-1 function could be controlled by defective expression, 
or variant slicing induced different isoforms rather than direct interaction with other 
proteins. Apaf-1 deficiency-induced resistance to apoptosis was previously reported in 
melanoma and leukemia cell lines (Jia et al., 2001; Soengas et al., 2001). Consistent 
with prior observations in Apaf-1-defective murine fibroblasts and thymocytes 
(Yoshida et al., 1998), the Apaf-1-deficient melanoma cells exhibited diminished 
apoptosis in response to doxorubicin, and this defect was reversed when Apaf-1 
expression was restored by demethylating agents (Soengas et al., 2001).  
Apaf-1 localization is a key issue in the present study. Apaf-1 has been reported to 
reside exclusively in the cytosol, in various cell lines (Hausmann et al., 2000). Its 
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homologue CED-4 stays in mitochondria due to interaction with CED-9 (Bcl-2 family 
members) Previous studies showed, however, a different Apaf-1 localization when 
cells are undergoing apoptosis or upon overexpression of Bcl-2 (Ruiz-Vela et al., 
2001; Ruiz-Vela et al., 2002; Seiffert et al., 2002). Furthermore, the nematode 
homologue of Apaf-1, CED-4, interacts with the Bcl-2 homologue, CED-9, and is 
thus localized to mitochondrial membranes in normal cells (Martin, 2002). Data 
presented have provided a new, potential mechanism of chemoresistance in human 
BL cells: plasma membrane sequestration of Apaf-1, resulting in a failure to initiate 
intrinsic caspase-dependent apoptosis. Importantly, liberation of plasma membrane-
sequestered Apaf-1 in Raji and DG75 cells by disrupting lipid rafts with MCD 
sensitized these cells to the chemotherapeutic drug, etoposide.  
Why Apaf-1 is sequestered in the plasma membrane in the Raji cell line is an 
intriguing question. Aberrant distribution that could be due to Apaf-1 mutation was 
excluded at least in the present study. Some possibilities are that Apaf-1 could interact 
with lipid raft-associated proteins such as, for instance, the EBV-encoded latent 
membrane proteins LMP1 and LMP2 (Higuchi et al., 2001), or, alternatively, Apaf-1 
might interact with membrane-associated cytoskeleton structures, since WD40 
domain-containing proteins have the potential to interact with the cytoskeleton (Smith 
et al., 1999). The lipid component or structure could also change the intracellular 
biophysical environment, thereby interfering with the protein-lipid interactions.  Lipid 
raft binding or associating proteins have been reviewed by Simons and Munro (Munro, 
2003; Simons and Toomre, 2000). It has been suggested that such rafts could play an 
important role in many cellular processes including signal transduction, membrane 
trafficking, cytoskeleton organization, and pathogen entry. However, rafts have 
proven difficult to visualize in living cells. Most of the evidence for their existence 
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and function relies on indirect methods such as detergent extraction, and a number of 
recent studies have revealed possible problems with these methods. Direct studies of 
the distribution of raft components in living cells have not yet reached a consensus on 
the size or even the presence of these microdomains, and hence it seems that a 
definitive proof of raft existence has yet to be obtained. But indeed, composition of 
lipids, especially cholesterol and sphingosine, contribute to redistribution of proteins 
on the plasma membrane. Previous studies have demonstrated significant difference 
in the plasma membrane composition in Raji BL cells from the apoptosis sensitive 
cell line, Jurkat cells (Kagan et al., 2002). Although experiments described here failed 
to find any differences in Apaf-1 between different cell lines at mRNA level, the 
possibility that post-translational modulation on Apaf-1 could change somehow 3D 
structure of Apaf-1 or its interaction with membrane components could not be ruled 
out. Basal levels of reactive oxygen species (ROS) in Raji cells is much higher than in 
Jurkat cells, this physiological oxidative stress could also influence protein and 
cholesterol trafficking in the cells (Parat et al., 2002). These different candidate 
mechanisms need to be further investigated in BL cells, especially their possible 
relationship to chemoresistance.  
 
2. Intracellular requirements for post-mitochondrial molecules, such as the IAPs, 
to control apoptosis in BL-derived cell lines 
 
Apoptosis downstream of the mitochondrion can be viewed as a two-signal system. In 
addition to cytochrome c, which induces apoptosome assembly, full caspase 
activation requires a second mediator that relieves the intrinsic inhibition by IAP 
proteins when they are present (Arnt et al., 2002). This model suggests that a 
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deficiency of either signal will inhibit apoptosis. Consistent with this model, although 
microinjection of cytochrome c may kill some cells (Samali et al., 1999), this is not 
true in all cases (Li et al., 1997a); furthermore, transfection with Smac alone may also 
be insufficient to trigger apoptosis (Du et al., 2000; Fulda et al., 2002; Guo et al., 
2002; Jia et al., 2003; Srinivasula et al., 2000). This model also predicts that XIAP 
gene deletion should enhance apoptosis whereas Smac deletion should inhibit; 
however, at least in mice, the results have been unexpected. Hence, targeted deletion 
of either XIAP (Harlin et al., 2001) or Smac (Okada et al., 2002) failed to produce an 
obvious alteration in apoptosis. Nevertheless, several groups have reported on the 
effect of Smac-based peptides on chemotherapy-induced apoptosis (Arnt et al., 2002; 
Fulda et al., 2002; Guo et al., 2002; Yang et al., 2003a). These striking effects have 
stimulated interest in Smac-based drug design, and small chemical compounds where 
mimic Smac are currently being developed (Li et al., 2004). However, some issues 
need to be resolved before its application to clinic. First, what is the intracellular 
background or milieu needed for Smac-based execution of cell death? For instance, is 
the initiation of apoptosome formation needed or not for this event to occur? Second, 
could Smac peptides or mimics actually initiate apoptosis, or do these agents serve to 
enhance caspase activation in a conditional manner (i.e. only when other key players 
are present)? This point is very important because if Smac peptides could only 
potentiate or accelerate pre-existing apoptosis activities, then from the point of view 
of clinical application, Smac peptides could only be used in combination with other 
treatments, and only in cancer cells that already show some degree of sensitivity to 
apoptosis. Finally, gene disruption involves chronic alterations and provides a 
potential opportunity for compensatory changes in other regulatory components of 
apoptotic pathways (Harlin et al., 2001; Okada et al., 2002). For instance, cIAP1 and 
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cIAP2 levels are increased in XIAP-deficient mice and the changes in cIAP1 and 
cIAP2 expression may provide functional compensation for loss of XIAP during 
development or upon the induction of apoptosis. Similarly, the existence of a 
redundant molecule or molecules may be capable of compensating for a loss of Smac 
function in Smac-knockout animals. In contrast, treatment (of cancer cells) with 
Smac-peptides might produce acute changes in the function of IAPs without the 
opportunity for compensation. The results from experiments in the current project 
have clarified several aspects which could guide the future clinical utilization of Smac 
peptides or small chemical compound mimetics. Even though in Apaf-1-over-
expressing Raji cells, cytotoxic drugs could only induce cell death at rather late time 
points, 48 h to 72 h. However, Apaf-1 expression provides the necessary platform for 
Smac peptides to execute its function, resulting in a potentiation of cell death at 
earlier time points (16 h). Without this background of a sufficient, supra-threshold 
level of cytosolic Apaf-1, Smac peptides showed no effect, at least in the BL model. 
From the point of the two-signal pathway discussed above, the first signal, 
cytochrome c release and apoptosome assembly, might be needed for the second 
signal, Smac release and full-blown caspase activation. And results presented in this 
thesis also suggest that the Smac peptides function to accelerate apoptosome function 
and caspase activities by neutralizing IAPs, rather than by initiating apoptosis. 
Elegant data have shown that cell differentiation in the neuronal-derived cell line, 
PC12, is linked to a reciprocal regulation of Apaf-1 and IAPs, such that a decrease in 
Apaf-1 expression was observed concomitant with an increased ability of IAPs to 
regulate apoptosis (Wright et al., 2004). However, in light of the work presented here, 
it could be concluded that Apaf-1 is crucial for apoptosis induction, whereas IAPs are 
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able to modulate the efficiency of apoptosis. Moreover modulation of IAPs alone is 
not sufficient to trigger apoptosis, at least not in BL-derived cell lines. 
As discussed before, IAPs primarily function to attenuate caspases activation by 
different ways. In the panel of BL derived cell lines used in these studies, in general, 
IAPs are highly expressed. Even though complete apoptosome formation and function 
is the key to initiate apoptosis in BL cells, IAPs still could be candidate targets to 
manipulate to sensitize BL cells to apoptosis, or at least could serve as adjunct 
treatments with other agents. There is accumulating evidence that IAPs may have a 
role in the development of cancer besides their apoptosis inhibitory function, 
suggesting that IAPs may contribute to tumor cell survival, and as such, could be 
potential targets for therapy. Chromosomal translocation of c-IAP2 causes aberrant 
expression of a chimeric IAP-MALT1 gene in mucosal associated lymphoma. 
(Dierlamm et al., 1999) Amplification of cIAP1 is implicated in esophageal squamous 
cell carcinoma, (Imoto et al., 2001)  and ML-IAP is over-expressed in melanomas. 
(Vucic et al., 2000) Over expression of survivin is common in a variety of cancers, 
although whether this is causative in terms of inhibiting apoptosis or is a consequence 
of the enhanced proliferation of tumor tissues is unclear (Altieri, 2003). XIAP 
expression is elevated in a number of cancers, and the expression level of this gene 
has been correlated with poor prognosis (Tamm et al., 2000).  In addition, the XIAP 
interacting protein XAF1 has been suggested to be a tumor suppressor gene, with low 
expression in tumor lines (Fong et al., 2000; Liston et al., 1997) and gastric tumor 
samples.   
 Studies in tumor cell lines have demonstrated that inhibition of IAPs function can 
sensitize cells to apoptosis. Indeed, in this study, inhibition of IAPs by two different 
ways, immunodepletion of IAPs by specific antibodies in vitro and neutralizing IAPs 
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by introduction of exogenous Smac N7 peptide in whole cells, sensitized BL cells to 
apoptotic triggers. Moreover, specific inhibition of XIAP itself provides evidence that 
inhibition of IAP activity may be a viable therapeutic strategy (Arnt et al., 2002; 
MacKenzie and LaCasse, 2000; Yang et al., 2003a).  Small molecule inhibitors of 
XIAP have recently been identified by high through-put screening of combinatorial 
libraries of polyphenylurea compounds for the ability to relieve XIAP repression of 
caspase activity (Schimmer et al., 2004).  This screen identified molecules that are 
able to induce apoptosis in tumor cells and inhibit tumor growth in xenograft models, 
whilst exhibiting little toxicity to normal tissues. In addition the drugs were able to 
cooperate with a broad range of cytotoxic agents, including irradiation, 
chemotherapeutic agents and the death receptor ligand TRAIL. These inhibitors may 
have potential for broad applicability as chemo-sensitizers for agents that trigger 
activation of caspases.  
 
3. Cytochrome c and Smac release in BL cells  
 
As mentioned before, the promising clinical application of Smac peptide is not 
sufficient enough to trigger apoptosis by itself. At least in BL cell model, it depends 
on the complete downstream mitochondria signals, such as Apaf-1. When compared, 
cytochrome c and Smac release in panel of BL cell lines in this model showed 
different release patterns in different cell lines, even though they share the similar 
genetic background. As seen in Figure 15, 34 and 42, most cell lines, including 
resistant cell lines, exhibited cytochrome c release under different triggers except 
DG75 cells. Smac release was hardly detected in most resistant cell lines, including 
Raji and DG75 cells. At least, based on the data from staurosporine experiments, it 
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could be argued that Smac release correlated better with cell sensitivity to apoptosis, 
instead of cytochrome c release. These data have been corroborated by similar 
findings that cytochorme c and Smac release could be variable in different models, 
which could influence cells response to apoptotic stimuli. However, in the absence of 
more direct evidence, it’s hard to draw conclusion as to the real mechanism of action 
of these small molecules during apoptosis. Both cytochrome c or Smac release and 
dissipation of mitochondria ∆ψm could be detected before caspases activation, 
thereby preventing a clear kinetic analysis. Real-time single cell analysis also could 
not answer this question based on the finding that fluorescent labeled cytochrome c 
and Smac release coincided with mitochondrial membrane potential depolarization. 
Furthermore, zVAD could not change Smac release kinetics in MCF-7 cells, 
suggesting that Smac release might be caspase independent (Rehm et al., 2003). 
Another study from a Japanese group reported that UV irradiation triggered 
cytochrome c and Smac release at different doses. Low dose (150J/m) of UV 
irradiation could only induce cytochrome c release but did not induce apoptosis, 
however, increasing the UV to 500J/m triggered Smac release and significant 
apoptosis. Furthermore, the level of XIAP was decreased in the latter case. It was 
suggested that the extent of Smac efflux from mitochondria is a determinant whether 
a cell will undergo apoptosis or survival (Takasawa and Tanuma, 2003). Data shown 
here also confirm that, whereas the key to Apaf-1 oligomerization and formation of 
the apoptosome, Smac release is a critical determinant of cell sensitivity to apoptosis 
in the presence of optimal cytosolic Apaf-1 in BL cells.   
Several well-known mechanisms have been shown to regulate cytochorme c and 
Smac release in apoptotic cells. Bcl-2 family members, especially the truncated BH3 
only protein tBid have been well studied.  It was first shown by Madesh et al that tBid 
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evoked a rapid and essentially complete release of cytochorme c and Smac/Diablo 
from every mitochondrion in the visualized individual cell. Both cytochrome c and 
Smac release triggered by subnanomolar tBid started after 10s delay, however, the 
loss of ∆ψm lagged slightly behind small molecules release (Madesh et al., 2002). At 
least in the lactacystin induced model of apoptosis, cytochrome c and Smac were 
released independent of the drop of ∆ψm. In this study, the expression of Bcl-2 and 
Hsp27 proteins was also compared with cytochrome c and Smac release pattern in BL 
cells following exposure to staurosporine. In Raji cells, cytochrome c but no Smac 
release was detected and no Hsp27 expression was found. On the other hand, there 
was neither cytochrome c nor Smac release in DG75 cells that expressed both Bcl-2 
and Hsp27. Could we then draw the conclusion based on this simple finding that in 
BL cells, cytochrome c release could be regulated by Hsp27 and that Smac release 
might be dependent on Bcl-2 expression? Recent findings point to a role for both 
Hsp27 and Bcl-2 in cytochrome c and/or Smac release. Perhaps a more definitive 
answer could come from experiments designed to knock down Hsp27 or Bcl-2 (by 
siRNA) or alternatively overexpress these proteins to study their effect on cytochrome 
c and Smac release.  
 
4. Alternative apoptosis window opened in chemoresistant cells  
 
Different types of apoptosis are characterized in mammals, caspase dependent and 
independent. Tumor cells have acquired mechanisms to evade apoptosis by alternative 
ways, which provide novel targets bypassing the block in death signaling. More recent 
findings have highlighted the presence of both caspases dependent and independent 
mechanism of apoptosis in tumor cells. Classical apoptosis culminates in the 
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interneucleosomal fragmentation of genomic DNA into fragments of multiple 180bp 
in length. This phenomenon is strictly dependent on caspase-3 like proteases as 
described earlier. However, the presence of caspases independent apoptosis has been 
reported in a number of scenarios (Ishitsuka et al., 2005; Pozo-Guisado et al., 2005; 
Youn et al., 2005).  One of the mechanisms of caspases independent cell death could 
be other small mitochondrial intermembrane proteins, such as apoptosis inducing 
factor (AIF) (Cande et al., 2002), although there is a significant amount of debate on 
whether AIF mediated caspase independent cell death (Arnoult et al., 2003).  
Interestingly, in the final part of this study, both caspase dependent and independent 
cell death were observed in one cell type following staurosporine-induced apoptosis. 
Indeed, in an earlier report, staurosporine was shown to bypass resistance of 
melanoma cells to caspase-dependent apoptotic pathway by simultaneously activating 
both caspase-dependent and –independent apoptosis (Zhang et al., 2004). Ramos cells 
were resistant to etoposide induced cell death due in part to defective apoptosome 
activation. Staurosporine and lactacystin triggered efficient apoptosis in Ramos cells 
that was independent of caspases activation, suggesting that both these agents 
somehow skip the post-mitochondria defects in cells. Could another sensitive window 
be opened to kill chemoresistant cancer cells when the caspase-dependent apoptotic 
signaling pathways are defective? The important mechanism behind the caspase-
independent apoptosis remains to be evaluated.  
 




Although the demonstration that Apaf-1 sequestration may render cancer cells 
resistant to treatment, our data obtained in the Raji cell line are too limited to draw 
general conclusions concerning chemoresistance in all BL-derived cell lines. We do 
not exclude the possibility that other mechanisms might also be involved. Our 
preliminary data do show that several known inhibitors of apoptosis are expressed at 
high level in these cell lines, including Bcl-2 and Hsp27, both of which have been 
shown to target mitochondrial apoptosis events. However, when Hsp27 protein level 
were suppressed in DG75 cells, this did not sensitize cells to chemotherapeutic drugs 
or to other cytotoxic reagents which target the mitochondrial apoptosis pathway, such 
as betulinic acid, a natural compound that releases Smac from isolated mitochondria 
(Fulda et al., 2002). Therefore, Bcl-2 and Hsp27 might functionally compensate for 
each other. In addition, in DG75, both Hsp27 and Bcl-2 were detected, and perhaps 
both molecules must be silenced to overcome resistance in this cell line. The 
contribution of EBV-encoded proteins such as LMP1 in the modulation of apoptosis 
in EBV-positive BL cell lines should also be taken into consideration. 
Notwithstanding these possibilities, MCD treatment of DG75 cells was sufficient to 
sensitize towards etoposide, providing further support to the notion that Apaf-1 
expression in the cytosolic compartment is of crucial importance for apoptosis 
induction in BL cells. 
 
6. Proteasome in apoptosis and cancer therapy 
 
Numerous data from preclinical and basic research support the role of proteasome 
inhibitors as improvising target for cancer therapy. Ubiquitin-proteasome dependent 
proteolysis serves to degrade cellular proteins. However, apoptosis is regulated by 
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different proteolysis system, for instance, caspases, a family of specialized cysteine 
protease. Nevertheless, there is plenty of evidence of crosstalk between apoptosis and 
ubiquitin-proteasome system, whose function in apoptosis appears to be very complex. 
Proteasome inhibitors induce apoptosis in multiple cell types, while in other they are 
relatively harmless or even prevent apoptosis induced by other stimuli. Proteasome 
degrade specific proteins during apoptosis, but on the other hand some components of 
the proteasome system are degraded by caspases (Sun et al., 2004). The knowledge 
about the involvement of the ubiquitin- and proteasome-dependent system in 
apoptosis is already clinically exploited. Proteasome inhibitors are also widely used to 
treat variant types of cancer cells in preclinical experiments. However the involved 
mechanism is still unclear since proteasome inhibitors seem widely target not only 
apoptotic pathways but also cell proliferation pathways, therefore multiple targets 
have been proposed by different groups. Results presenting here show that 
proteasome inhibitor, lactacystin could kill BL cells. And it is the first to show that 
lactacystin induced cell death is Apaf-1 dependent in BL cells, as seen from Apaf-1 




This work provides evidence that Apaf-1-dependent apoptosome activation is a 
crucial factor in determining the response of BL cells to chemotherapeutic drugs and 
other pro-apoptotic agents that act via the intrinsic signaling pathway. Specifically, 
the initiation of mitochondria-dependent apoptosis requires a sufficient level of Apaf-
1 in the cytosolic compartment. These findings are also the first to show Apaf-1 
sequestration in the plasma membrane in cancer cells, and provide strong evidence 
that this may render cancer cells (in this case, BL-derived cells) chemoresistant 
(Figure 46). Furthermore, even under conditions of apoptosome formation, apoptosis 
may still be retarded by post-mitochondrial inhibitors such as members of the IAP 
family. Neutralization of these inhibitors can be regulated by the pro-apoptotic protein, 
Smac, which is released from mitochondria. In this study, exogenous Smac peptides 
were shown to potentiate apoptosis of BL-derived cells, but only when Apaf-1 was 
sufficiently expressed. Data are also presented and demonstrated that proteasome 
inhibition-dependent apoptosis requires Apaf-1 expression. The latter finding is of 
potential clinical importance, since proteasome inhibitors are currently being tested in 
clinical trials for the treatment of various malignancies (Rajkumar et al., 2005). Our 
results predict that proteasome inhibitors, and Smac-based therapies, may only be 
useful against tumours when Apaf-1 is expressed above threshold levels. Hence, 
profiling of cancer cell expression of apoptosis-regulatory molecules will be of 
importance in order to predict which patients might benefit from such treatments. 
Future studies should aim to determine the mechanism underlying Apaf-1 
sequestration in the plasma membrane, and whether defective cytosolic expression of 
Apaf-1 is involved also in primary BL tumors. Furthermore, it remains to be 
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established whether the IAPs, and other apoptosis-inhibitory molecules, are elevated 
in BL tumors in patients in general. And additional basic research efforts should be 
focused on other modulators of the apoptosome and of post-mitochondrial apoptosis 
signalling in BL cells, such as the PHAP proteins and prothymosin-α (Jiang et al., 
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